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GUIDELINES 
The purpose of the UWO Medical Journal is to provide a ingle forum for original articles based on clinical or research medicine of topical or historical 
interes t. Since readership of the Journa l is 
interdisciplinary, articles published will attempt to reflect 
a wide range of medical interests. In this regard, 
submissions hould be directed towards the general 
medical reader. Articles which do not pertain to the 
feature topic will be given lower priority as will those with 
excessive technical jargon. Please restrict submissions to 
under 2,000 words. 
Informal peer review is required, i.e., non-specialist 
authors are encouraged to collaborate with, or at 
minimum, have their work reviewed for conten t by a 
pecialist in the field . This individual, if not a co-author, is 
to be acknowledged at the end of the paper. In addition, it 
is recommended that all submissions be proof-read for 
significant stylistic or grammatical error . The editors will 
not assume re ponsibility for correction of this nature 
and articles requiring such revisions will be returned to 
the author. 
Submissions are to include a cover letter, two double 
spaced paper copies, and the full text on 3.5" computer 
diskette in Microsoft Word or WordPerfect format. The 
cover letter should be signed by all authors and indicate 
that the manuscript has not been published previously. 
Figures should be professionally d rawn; 
photocopying of illus trations from texts, without the 
permission of the publi her, is copyright infringement. 
Figures and tables should each be submitted on a separate 
page and any illustration with a grey-scale should be in 
the form of a photograph. Two copies of figures or tables 
should be included with labels on the back indicating 
number as well as the first author. Legends, which are to 
be included at the end of the text, should star t on a 
separate page with arabic numerals corresponding to the 
figures and tables. 
Submis ions and disk become the property of the 
Journal. The Journal reserves the right to correct errors of 
punctuation and spelling. Short biographical notes on the 
authors are to be included at the beginning of each paper. 
Affiliation with UWO is not a prerequisite for authorship. 
The U. W.O. Medical Journal is an interdisciplinary 
medical science publication, established in 1930. The 
Journal is published twice each academic year: Winter, 
& Spring. Subscription is $17.00 per year. © All 
material published in the U. W.O. Medical Journal is 
copywright protected-no section of the U. W.O. 
Medical Journal may be reproduced withou t the 
expressed written permission of the Editor. 
TO AUTHORS 
References are indicated numerically in the text1 and 
listed a endnote in order of appearance.2 Do not use 
the 'endnote' feature of your word processing program; 
list references as part of the text on a separate page 
immediately following the bod y of the document . 
Punctuation come before reference numbers and 
sentences are separated by one space only. Examples of 
Journal reference format follow below: 
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Apnea Syndromes. New York: Alan R Liss, 1978:23-46. 
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Ontario, London, Ontario, 6A 5Cl. Tel: (519) 661-2076. 
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will not be accepted for publication. 
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journals, like fashions, change with the times. 
A t its debut in 1930, the UWO Medical Journal was a paperback-sized volume of about 50 pages, devoted mainly to cientific review articles and, 
somewhat later, research abstracts and book reviews. Its 
advertising emphasized medical upplies, including golf 
clubs, "elixirs", and the "highly palatable" quick-energy 
beverage, Vi-Tone. Among the Journal's arly 
contributors were some unknowns who later ro e to 
celebrity, notably Murray Barr of "Barr-body" fame, who 
wrote several article as a student and fledgling 
physician, including a charming piece on moulding brain 
models out of clay as a way of learning neuroanatomy. 
The Journal's original format and spare, elegant 
design survived with only minor changes through the 
Great Depression and World War II. But by the early 
fifties, its clinical austerity was softened by a regular 
feature called "In a Lighter Vein", which offered local 
medical humour and poetry. Seldom anthologized, much 
of this poetry can be found only in the back issues of the 
Meds Journal. Starting about 1965, the Journal passed 
through a rapid eries of metamorpho e , changing its 
look almost yearly until, in the late eighties, it had 
slimmed down to 10 or 15 pages, with sports roundups, 
ocial calendars and comics pages called "In Stitche " and 
"Leisure Seizures". 
Then came a major change behind the scenes. Since 
its incep tion, the Journal had been published by the 
Hippocratic Society, now known as the Hippocratic 
Council. But in the early ninetie the Journal became 
independent of the Council. Under the new regim , the 
page count grew, there was a renewed empha is on 
educational articles, and each issue was built around a 
special feature topic to provide a focus. At the same time, 
we acquired Willow Press as our printer and our 
advertising was contracted out to View-an-Ad, thus 
guaranteeing the funds to publish two issues a year. 
These changes have resulted in a eries of exc llent 
publications. But they have also limited involvement in 
Journal activities to a handful of tudents. Moreover, 
almost all of the articles we have received in recent years 
have been scientific or clinical. While this type of article 
will continue to be a focu of the Journal, we have now 
taken steps to expand our cope by establishing regular 
columns on Promotion and Prevention, History of 
Medicine, Ethics, and Medical Myths. The first 
installment of Promotion and Prevention appears in this 
issue, and all four columns should be up and running in 
the next edition. We ha e brought on four new taff 
member to seek out and edit material for these sections, 
but we want to enlarge our contributor base much 
further, by inviting article from other faculties or even 
from outside the Univer ity, and by inciting more of our 
readers to make their mark on these pages. 
For the future, we aim to computerize further the 
Journal's operations, and to establish a peer-review 
procedure, which will improve the quality of the 
contributions and will also expose students to the real-
world process of publishing a scientific paper. I hope that 
all these change , in the works and yet to come, will 
increase participation in the Journal and make it a wider 
forum for the enlightenment of the medical community 
on scientific, ethical and hi torical topics. 
Our next is ue will feature ew Technologies in 
Medicine. If you are interested in writing or doing 
graphics on this topic, or for any of the regular sections, 
please contact me or one of the other editors. When your 
piece is published, mention it in your CV. I urge you to 
follow Dr Murray Barr's footsteps to greatness by 
contributing to the UWO Medical Journal. 
Ctil{/y JfoJII!.:iils, 
'Ed!lor 
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AN INTERVIEW WITH 
MEDICAL GENETICIST 
DR JACK JUNG 
"Do you like dinosaur ?" 
the doctor asks the little 
boy. A timid 7-year-old 
sitting on his mom's lap 
silently nods. 
"What kind of dinosaur is 
this one?"- Dr Jung points 
to a model on his desk. 
"A long neck", the child 
triumphantly replies. 
And so a bond is made. 
-Dr fung in the midst of a day of 
clinical practice at the Regional 
Medical Genetics Centre 
(RMGC) of the London Health 
Science Centre, Westminster 
Campus. 
Medical genetics may not be the first specialty that comes 
to mind w hen pondering the poss ibilities of a career in 
medicine. Dr fung hopes that this is changing. Through this 
interview, one gets a sense of the excitement of being in a 
g round-breaking f ield that successfully combines man y 
cl inically fa scinating iss ues w ith f undamental biolog ical 
questions. This is a profile of a man who truly loves his work as 
a medical geneticist. 
Dr Jack Jung is the director of the Regional Medical Genetics Cen tre (RMGC), an institution which works in partnership with many program of the 
London Health Sciences Centre. He is also a father to 
two beautiful girls, aged 3 and 7, whose picture he 
proudly displays in his office. Chat with him for a while, 
and you 'll soon discover he is also an avid fan of fl y 
fishing. 
HOW TO BECOME A MEDICAL GENETICIST 101 
Dr Jung began his undergraduate career in the early 
seven ties at the University of Bri tish Columbia in a 
general biology program. His first introductory course 
to genetics was taught by Dr Tony Griffi ths, former 
president of the Gene tics Society of Canada, whose 
clarity in the presen tation of persuasive logic was 
apparently captivating. Dr Jung was encouraged by Dr 
Griffi ths and another prominent geneticist, Dr David 
Suzuki, to enter into a program of genetic science. After 
by Lisa A. Calder BScH, M eds 2000 
completing an honours degree in genetics, Dr Jung 
embarked on what he terms an "adventure" at the 
University of Calgary in the undergraduate medical 
degree program. At the time, the medical school was in 
its infancy; beginning a new curriculum that 
emphasized self-directed learning to such a degree that 
examinations were non-manda tory. Students were 
obliged to write a comprehensive exam at the end of 
their third year in the program; but the freedom to 
pursue one's own learning objectives was much enjoyed 
by Dr Jung. Upon completing his MD, he pursued 
specialty training in paediatrics, following which he was 
inv ited by Drs Judith Hall and David Smith at the 
University of Washington to train in medical genetics. 
Equipped with a Canadian Medical Research Council 
post-doctoral fellowship, Dr Jung moved to Seattle. 
Monoclonal antibodies became the focus of hi s 
research in Seattle, as he worked towards identifying 
specific differentiation proteins hypothesized to be 
involved in the development of stem cells. The model 
used for testing this hypothesis was the switching of 
foetal haemoglobin to adult haemoglobin. Ba ic science 
research impressed him and he mar els at how "it is still 
a major challenge to try and understand very basic 
biological phenomena". 
Following his fellowships, he eventually found his 
way to London. He was attracted to London because of 
its relati vely small s ize, allowing for professional 
development and the po sibility to effect a significant 
impact. Having now been here for 15 years, he confirms 
he undoubtedly made the right choice: "It's a sense of 
balance that holds me here ... balance of personal life with 
professional, balance within professional work between 
clinical and academic work and teaching ... " 
CLI NICAL R ESEARCH- RELATING CLINICAL 
SCENARIOS TO BIOLOGY BASICS 
Indeed Dr J ung does balance a variety of roles : 
clinician, teacher, administrator and researcher. The 
major thrust of Dr Jung 's research has been clinical 
dysmorphology. He contends that while many associate 
this area with the study of very rare genetic syndrome , 
" I feel very strongly that these challenging clinical 
scenarios are important links to questions of basic 
(science) research ... " He exp lains that clinical 
d ysmorphology involves the recognition of unusual 
developmental problems as distinct clinical entities, that 
U. W .O. Medical Journal 66 {1) 1996------------------------- 7 
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in alliance with basic science can be explored at the 
molecular level. Dr Jung comments that, "through the 
use of a combination of molecular, biochemical, and 
cytogentic techniques, scientists have been able to link 
genes to clinical phenotypes identified by clinical 
dysmorphologists ." Dr Jung also pointed out that this 
kind of knowledge is essential to developing potential 
therapies for the e genetic conditions. 
Other avenues of Dr Jung's research have included 
several studies related to neurofibromatosis ( F), an 
autosomal dominant disease characterized by 
subcutaneous benign tumours and cafe-au-lait spots. 
His work with his colleague in thi area has included 
characterizing a mutation of the NF-1 gene, de eloping 
a polymerase chain reaction (PCR) based approach to 
molecular and prenatal diagnosis of F-1 and 
clarifying the relationship between familial segregation 
of phenotype and mutation of the F-1 gene. 
Further recent work has looked at the cardiac 
creening of children with Down's yndrome and, in 
another study, the genetic predisposition for the 
everity of foetal alcohol syndrome. In addition, the 
RMGC is currently involved in a large multicentres 
clinical trial dealing with breast cancer, that is funded 
by the American ational In titute of Health. One of 
the objectives of the trial is to determine the regional 
YOUR SUCCESS 
IS VVITHIN RE 4 CH 
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frequency of the various types of mutations of BRCA1, 
a recently discovered breast cancer gene. While the 
study i anticipated to run for 3-4 years, Dr Jung says 
that the RMGC and London Regional Cancer Centre 
have already enrolled over 100 families with a very 
high incidence of familial cancer. They are currently 
undergoing genetic analysis. 
SOME OF THE PARAMETERS OF CLINICAL 
GENETICS PRACTICE 
While Dr Jung is very involved in genetics 
research, he indicates that his true love remains with 
clinical work and teaching. Over the years, many of the 
exciting advances in genetics have had far-reaching 
implications. Dr Jung's practice of medical genetics has 
evolved from being primarily oriented toward 
paediatric issue to encompassing a significant adult 
population, who present with questions about familial, 
hereditary and late onset cancers or neurodegenerative 
disea es. He al o notes that prenatal coun elling is 
evolving and has to keep pace with the rapid 
developments i n very disease-specific molecular 
genetic technologies. 
Another important component of his practice as a 
medical geneticist is genetic counselling: "I don't think 
there is any great mystique to genetic counselling- it is 
based on good principles of medical practice. When 
patient or familie present them elves to a doctor, it's 
that process of imparting information so that i t 's 
under tandable to the patient and the family tha t is 
important." 
SHARING KNOWLEDGE WITH THE NEXT 
GENERATIO 
One of the key to successful genetic counselling is 
good communication. In observing him interact with 
his patients and their families, it is clear the Dr Jung is 
a gifted communicator. This also comes across in the 
genetics cour e he teaches in Phase I of the 
undergraduate medical program at the University of 
Western Ontario. Dr Jung structures the course such 
that fundamental genetic principles are illustrated 
through actual di cussion with patients during 
lecture . 
"My personal teaching philosophy is to how real 
life situations that will help the students understand 
why the basics need to be understood (for example a 
biochemical pathway or the structure of D A). When 
students get a chance to be faced with real questions 
being posed by the e individuals, it gives importance 
and rele ance for the need to understand ba ic a pects 
of biology." 
In listening to their stories and watching Dr Jung 
interact with h is patients, first year students are 
learning about the importance of good communication 
as well a the ba ic of genetics. The impact Dr Jung 
has had on his student is reflected in the teaching 
award he has received from the UWO Faculty of 
Medicine and Department of Paediatrics. 
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WHAT DOES TH E FUTURE HO LD? 
When asked what he think will be "hot" in 
genetics in the near future, Dr Jung suggests that some 
of the research focus will shift from monogenic 
disorders to polygenic, multifactorial diseases such as 
the hyperlipidemias, diabetes and hypertension. In 
addition the fundamentals of cell differentiation and 
the process of embryological development need to be 
further understood. Finally he believes genetic 
diagnostics will expand and develop even more rapidly 
and that increasing opportunities for gene therapy are 
not far off the horizon. 
In personal terms, one of Dr Jung's future goals is 
to increase his involvement in medical education. His 
contagious excitement about his specialty is something 
he hopes to be able to pass on to others. 
"I've always considered myself extremely fortunate 
because within my chosen specialty, you see clinical 
problems that frequently pose relevant questions in 
terms of basic science - it's a bridge that you can't get 
away from in clinical medial genetic practice ... (It's) 
more challenging to try and make this connection and I 
hope more of the younger generation will pursue 
this ... " 
H ISTORY OF TH E REGIONAL MEDICAL 
GENETICS CENTRE (RMGC), LONDON H EALTH 
SCIENCES CENTRE' 
1921-1945 
1949-1969 
1965 
1972 
1974 
• Dr Madge Macklin provides advice to 
local physicians on genetic matters. After 
publishing over 100 genetic-related 
articles, she is recognized as a pioneer in 
medical genetics in orth America and is 
elected president of the American Society 
of Human Genetics in 1959. 
• Dr Murray Barr publishes a 
neurohistological study identifying the 
sex chromatin body (Barr body) and 
pointing to its clinical significance. Over 
next 20 years he brings international 
recognition to the University of Western 
Ontario as Dr Barr is established as one of 
the founders of human cytogenetics. 
• One of Ontario 's first cytogenetics 
laboratories is instituted at Victoria 
Hospital. 
• A Genetic 
established 
Paediatrics 
Hospital. 
Counselling Clinic is 
in the Department of 
at the new University 
• The Birth Defects Evaluation Clinic is 
founded at the Victoria Hospital to 
provide prenatal counselling and genetic 
amniocentesis. 
Prof il e 
1980 • UWO Regional Medical Genetics and 
Birth Defects Service is based at CHWO 
on South Street. (The service later 
becomes known as the Regional Medical 
and Molecular Genetics Program of the 
London Health Sciences Centre) 
1981 • UWO RMGC is accredited for the first 
time as a "major centre for service" by the 
Canadian College of Medical Geneticists . 
1982 • Windsor Genetics Clinic is established as 
a direct outreach clinic of the RMGC. 
1995 • 420 different physicians in the 
Southwestern Ontario Region referred 
patients, couples or families to the RMGC. 
1996 • RMGC has seen more than 20,000 patients. 
The rate of growth in numbers of referred 
patients has averaged between 15 and 20% 
in each of the 16 years since the centre was 
founded. 
1 Adapted from: Soltan,H.G. Chronology of Significant 
Events in the Development of Human and Medical 
Genetics in London, October, 1996. 
Research 
means 
one thing. 
(if e. 
•• 
For thousands of Canadians, Sandoz research has meant a 
new lease on life following organ transplantation. Thanks to 
research into immuno-suppressant agents, people of all ages are 
celebrating successful transplantations. And so are we. 
We are celebrating more than ten years since our clinical trials 
began on an agent that has changed transplant medecine forever. 
And the research continues. 
Our research has meant a breakthrough for medicine. For 
thousands of Canadians, it means life. 
Research means life. 
A SANDOZ SANDOZ: CANADA INC. Dorval . Quebec H9R 4 P5 
U. W. O. Medical Journal 66 (1) 1996------------------------- 9 
P r omo ti on a n d P r e v e n t io n 
Children and the Prevention 
Heart Disease 
of 
A stitch in time save nine" is the central thrust of preventive medicine. It is much easier to employ preventive measure than to deal with the often 
me y consequence of an uncontrollable di ea e process. 
Therefore, if a di ease proce can be slowed or controlled 
during the early stages of life, severity of illness can be 
dra tically reduced later on. The paediatrician's role is 
therefore key to the management of many di ea e , not 
the least of which is cardiovascular disease, which is 
theoretically preventable by changing certain life tyle 
patterns. Healthy habit such as exercise and proper diet, 
and the avoidance of unhealthy habits such as smoking, 
should be lifelong lifestyle patterns which should be 
firmly entrenched a early as po ible. 
Coronary heart di ease is the leading cau e of death 
in orth America, re ponsible for over 500,000 death 
annually. ' Surprisingly enough, even though these 
numbers are not typically a sociated with the paediatric 
population, deaths are rarely due to a sudden 
pathological process. Rather, it is the endpoint of a 
lifetime of damage, a disease process that begins in 
childhood and early adolescence. It has long been known 
that fatty streaks, thought to be the pathologic precursors 
of atherosclerotic plaque, appear in childhood. Young 
American soldiers who died in the Korean war were 
shown at autop y to ha e disseminated evidence of 
atherosclerosis. ' This implies that aggressive early 
intervention is necessary to fight a disease that span 
many decade in its course. 
Cholesterol screening has been sugge ted, although 
not without controver y, a an early measure to identify 
candidates for cholesterol-lowering diets. This is 
controversial due to the fact that cholesterol levels may be 
high in childhood yet normal and without any 
pathological consequence later in life. It should 
nevertheless probably be implemented becau e a healthy 
diet early in childhood can have few if any deleterious 
effects, while promoting healthy lifestyle habit for the 
future. 
Although childhood hypertension is not common, 
prevention still must be a concern for tho e who care for 
children. Children who are obese have higher blood 
pre sure than their lean counterparts. Measures to 
address the prevention of hypertension should focus on 
appropriate dietary measures, including reduction of fat 
and salt. Furthermore, regular aerobic exercise plays an 
important role in the prevention of hypertension.2 
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Circulating blood lipid levels, cholesterol, physical 
inactivity, smoking and obesity should all be actively 
targeted by paediatricians, parents and school 
administrators. Healthy dietary patterns in children can 
greatly decrease the risk of heart disease, and therefore 
nutritional education at home and in school should be a 
prime concern. To this end, a student organization known 
as "Health Matters", establi hed by UWO med ical 
tudents, is planning to engage in a nutritional education 
program in local elementary schools. Their aim i not 
simply to inform, using the conventional didactic 
approach involving the four food groups, but also to 
change behaviours and attitudes about nutrition through 
the use of small group teaching. A family-oriented 
approach including practical nutritional teaching (label 
reading and recipe modification) combined with 
behavioural contracting techniques, and an exercise 
program has proven succes ful in the modification of 
cardiovascular ri k factors, including being overweight.< 
Habitual cigarette smoking, tobacco use, and aJcohol 
consumption are reported in one-third of adolescents and 
young adults. These habits have their roots in early 
childhood .3 (Tobacco companies realize that their 
customer ba e i dying, and that in order to maintain 
profits they must recruit a young generation of mok rs.) 
Tobacco companies in the United States have used 
advertising that appeals to young people. The adorable 
cartoon figure of 'Joe Camel' portrays to children and 
young adole cents that smoking is 'cool' and adorable. 
Even the Marlboro Man appeals to young adolescent 
through the use of 'cool' images linked to smoking. 
Legislation in Canada i aimed at limiting cigarette 
advertising in general, and pecifically at limiting 
marketing ploys aimed at children and young 
adolescents. Parents, teachers, legislators and 
paediatricians hould collaborate to ensure that the 
younge t of our population do not succumb to the pitfall 
of smoking. In young men who die in accidents, the 
increa ed occurrence of athero clerotic lesion in tho e 
who smoked tobacco compared with those who had 
similar cholesterol levels but did not use tobacco 
demon trates the need for early intervention. 2 
Paediatricians can also discourage smoking in parents, as 
passive smoking can also have deleterious consequences. 
Physicians should take an active role in educating 
children about the harmful and addictive nature of 
smoking. 
Phy ical inactivity has become of increasing concern 
as our society becomes more electronic and consequently 
sedentary. Phy ical activity hould be promoted at 
school, not only through physical education, but also 
through the encouragement of an active life tyle by 
parents and physicians. An a ociation has been found 
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between viewing television more than 2 hours per day, 
poor dietary habits, and eleva ted cholesterol levels in 
children. Television viewing should be limited to 2 hours 
or less per day, with a policy of no ea ting or drinking 
w hile w atching programs. Furthermore, a t leas t 30 
minutes of physical activity 3 days per week, in addition 
to that obtai ned from school phys ical education 
programs, is essentiaP 
Health promotion and disease prevention is probably 
as old as the practice of medicine itself. In recent history, 
the prevention of infec tious disease through the use of 
vaccines, antibiotics and improved antiseptic procedures 
has been remarkably effective. Almost every new HIV 
infection is entirely preventable, either through the use of 
sterile needles, condoms or community-based educational 
program about HIV transmission. Thus the importance 
of preventive medicine cannot be overemphasized. If one 
contrasts the high cost of hospital care after myocardial 
infarction with the small price of nutritional counselling, 
it becomes very evident that primary care and prevention 
can be the most cost-effective strategy in the promotion of 
cardiovascular health} 
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A rti c l es 
lnterventional radiology in a 
modern hospital setting 
INTRODUCTIO N 
I ntervention al radiology is a relatively new discipline that offers many services. It has emerged in the last 15 years to provide alternatives to many surgical 
procedures. The benefits of interventional procedures 
include local anaesthesia and sedation instead of a 
general anaesthetic, shorter recovery periods, lower cost 
and the ability to treat ill patients who are not surgical 
candidate Y Unfortunately, medical education has 
lagged behind these advances and the majori ty of 
medical students, while exposed to diagno tic 
radiology, are unaware of interventional radiology and 
the services that it provides . Thus, the focus of this 
article i to give medical students and clinician a 
simple, comprehensi e overview of the field. 
P ERIPHERAL A N GIOGRA PHY A N D VASCULAR 
INTERVENTIONS 
The root of modern interventional radiology are in 
cardiova cular procedures. Peripheral angiography, 
fir t performed in the 1920s, was neither practical nor in 
widespread use until the 1950 , when the Seldinger 
method wa introduced . Since then, angiography has 
developed from a purely diagnostic procedure to one 
that also allows therapeutic inter entions.3 Angioplasty 
has complication rates lower than surgery and patency 
rates, in properly selected patients, that are equivalent 
to those achieved with surgery.4 
Angiography is used to diagnose primary vascular 
di ease such as vasa-occlusive disease; to define the 
anatomy in arteriovenous malformation or aneUiy m ; 
and to localize small vascular tumours such as 
pancreatic insulinomas or parathyroid adenomas. 
Moreover angiography is performed prior to any 
therapeutic vascular procedure such as balloon 
angioplasty, thrombolysis, embolization, 
chemoembolization, stenting or atherectomy. 
Pre Uigical angiography is also performed to establish 
the vascular anatomy before tumour resections, 
transplant and revascularization procedures.5 
The absolute contraindication to any of the above 
procedure is a medically unstable patient. 5 Other 
relative contraindications include recent myocardial 
infarct, coagulopathies and pregnancy. 5 
In therapeutic angiography, the tool at the dispo al 
of the radiologist are the angioplasty balloon, and more 
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recently stents and covered tents. Most experience 
with percutaneous transluminal angioplasty (PTA) has 
been in the lower extremities and aortoiliac region. 
Vascular lesions have been classified into four 
categories ranging from category 1 where balloon 
angioplasty is the treatment of choice to category 4 
where surgery is preferred. This classification is based 
on the nature of the le ion (steno is vs. occlusion), its 
location, and it length .6 Endovascular stents make 
many category 3 and 4 le ions amenable to 
percutaneou therapy. Stents are also used when there 
is an unsatisfactory PTA result, as is the case in elastic 
recoil or intimal dissection.6 
Angioplasty techniques have recently been applied 
to the arteries of the head and neck. Carotid angioplasty 
is at pre ent re erved for cases of surgical failure or 
high risk patients that are not urgical candidates. 7 
Vertebral artery angioplasty is successful in properly 
selected patients with lesions at the origin of the 
vertebral artery and can be the treatment of choice for 
the e lesions.7 
Interventional procedure in trauma were 
classically restricted to diagno tic angiography. 
Following the in titution of le s invasive tests such as 
CT, the use of diagnostic angiography in this setting 
decreased. At pre ent, therapeutic interventional 
procedures have a role in selected trauma patients with 
internal haemorrhage. The goal of arterial embolization 
therapy is to stop bleeding and tabilize the patient. 8 
The use of covered endovascular stents for this purpose 
has also been described in some centres. The major 
limitation in the performance of the e procedure is the 
availability of a skilled interventional team, with a 
rapid respon e time, 24 hours a day, in an appropriately 
equipped level 1 trauma center. 8 A the benefits of 
emergency interventional radiology become apparent, 
the availability of these services will become more 
wide pread . 
Other indications for transca theter artery 
embolization, outside the trauma setting, include 
bronchial artery hemorrhage, obstetrical hemorrhage, 
gastrointestinal bleeding, arteriovenous malformations, 
testicular varices, bone tumour , high-flow priapism 
and chemoembolization of liver tumours.5 
CENTRAL VENOUS ACCESS 
Modern medicine often requires venou access for 
therapy and diagnosi (blood tests) . Therapies that 
require central venous acces (CV A) include 
haemodialysis, total parenteral nutri t ion and 
chemotherapy for microbial or neoplastic disease. 9 As 
the indications for these therapies continue to increase, 
the use of CV A will increase. 
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Although CV A catheters have traditionally been 
inserted by surgeons in the operating room (OR), 
pre ent standard practice in most institutions is to place 
these catheters radiologically. Advantages of 
radiological placement over surgical placement include 
a s horter waiting time (usually less than 24 hours), 
quicker recovery because general anaesthetics are 
avoided, and lower cost to the institution because 
radiological suites do not have the o erhead of an OR 
and a recovery room. 
CVA catheters can be placed in various sites 
including the antecubital veins (usually short-term), 
subclavian veins, internal jugular veins, hepatic veins 
and inferior vena cava. The selected route depends on 
the type of catheter, anticipated duration of access 
requirement and most importantly, the availability of 
sui table patent veins.9 
The long-term CV A catheters used at present have 
ei ther a subcutaneous tunnel or are attached to a 
subcutaneous port. The catheter is placed in two steps. 
First, venous access is achieved using standard 
percutaneous access techniques and a sheath is placed in 
the vein. The catheter is then tunnelled subcutaneously 
and placed in the vein through the sheath. When placing 
a port, a pocket is created subcutaneously for the port 
and then the catheter is tunnelled and placed as before.9 
With the present use of CV A catheters no longer 
confined to an inpatient setting, outpatients continue 
with activities of daily living while a CV A catheter is in 
place. This type of stress has forced catheter design to be 
improved, reducing thrombotic and infectious 
complications of long-term CV A.9 
A rticl e s 
GASTROINTESTINAL INTERVENTIONS 
One of the most common GI interventional 
procedures is placement of gastrostomy or 
gastrojejunostomy tubes . These procedures are 
preferentially performed radiologically as surgical 
placement is associated with delay in starting feedings, 
increased incidence of aspiration, wound infection and the 
possibility of a temporarily delayed gastric emptying 
tim. 5 e. 
The major indication for placing a gastrostomy or 
gastrojejunostomy tube is to provide nutritional support 
in patients capable of absorbing nutrients enterically when 
mechanical or functional disorders (e.g. head and neck 
lesions, neurological disorders) do not allow adequate 
feeding by mouth .5· ' 0 · ' ' Other indications include 
decompression in small bowel obstruction and in 
conditions associated with decreased gastric motility.5·" 
Contraindications for this procedure include the 
presence of a ventriculoperitoneal shunt (absolute), 
bleeding disorders, difficult percutaneous access, massive 
ascites, gastric wall lesions and abdominal varices.5 
Other GI procedures include caecostomies in children 
with faecal incontinence and dilatation of enteric 
s trictures. In malignant dysphagia, dilatation of the 
oesophagus may palliate otherwi e inoperable carcinomas 
of the oesophagus. Other diseases, including primary lung 
cancers and mediastinal masses, can also compromise the 
oesophageal lumen. Oesophageal dilatation and covered 
stent placement, not in widespread use at present, 
improve quality of life in patients with oesophageal 
dysphagia and oesophagorespiratory fistula. 12 
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A rticl es 
BIOPSY 
One of the most frequently performed procedures in 
interventional radiology is the image-guided needle 
biopsy. This technique can be used to sample most 
lesions in the chest, abdomen, pelvis, soft tissues and 
retroperitoneum. 11 Guidance for biopsy procedures is 
provided by ultrasound, computed tomography (CT), 
fluoroscopy, or combinations of the above. Success rates 
for radiological biopsies are typically very high and 
complication rates are low because of the use of small 
calibre needles. In a large series by Parker et al., 
adequate tissue for histology was obtained in 97% of 
cases and sampling of target tissue was obtained in 92% 
of cases when using a biopsy gun. 13 
ABSCESS DRAINAGE 
The development of percutaneous drainage as a 
first-line treatment of abscesses is partially due to 
advances in cross sectional imaging. Ultrasound and CT 
can document a safe access route to an abscess, allowing 
the interventionalist to avoid vital structures while 
approaching deep seated collections. 
Successful percutaneous drainage can be attained 
for abscesses in pelvic, pancreatic, retroperitoneal, 
hepatic, subphrenic, thoracic, splenic and 
musculoskeletallocations. 11 Although previously viewed 
as contraindications to percutaneous treatment, the 
presence of multiple abscesses, loculations or enteric 
communications do not preclude treatment 
radiologically at present. 11 •14 Other types of abscesses 
which previously would not have been treated 
percutaneously include lymphoceles, empyemas and 
amoebic or echinococcal abscesses. 1' When performing 
fine needle aspiration of an abscess for diagnostic 
procedures, organs and bowel may be crossed but when 
placing a drainage catheter a direct access route is 
preferred.5 Other patient conditions which require care 
are coagulopathies and access requiring the 
transgression of the pleural space.5 
Most abscesses can be cured with percutaneous 
therapy. Benign cysts treated percutaneously will often 
recur and require sclerosants to ablate their secretory 
surfaces. 14 Some complicated abscesses which are 
multilocular, purulent, contain necrotic tissue or have 
enteric communications may not be curable by 
percutaneous means. This situation most often occurs in 
patients with pancreatic abscesses, or abscesses caused 
by leaks from enteric anastomoses. In these cases 
percutaneous therapy is of temporizing benefit, helping 
the patient recover from the acute illness and allowing 
the surgeon to plan a definitive surgical cure electively. 11 
BILIARY AN D GALLBLADDER INTERVENTION S 
Endoscopic retrograde cholangio-pancreatography 
(ERCP), performed by endoscopists, is the preferred 
method for visualizing the biliary ductal system and 
placing stents for biliary ductal obstruction. When this 
procedure is unsuccessful or not possible, percutaneous 
transhepatic cholangiography (PTC) is performed. 
Although more invasive, PTC offers superior resolution 
of anatomic abnormalities in the biliary system when 
compared to other radiological methods (e.g. CT, US or 
nuclear medicine). 11 
The actual procedure involves placing a needle into 
an intrahepatic bile duct and then injecting contrast to 
delineate the ducts. This procedure is easier in a patient 
with a dilated biliary system but can be accomplished in 
85-90% of patients with non-dilated ducts. 11 As biliary 
infection is prevalent in patients with biliary 
obstruction, it is important to provide adequate 
antibiotic coverage with broad spectrum prophylactic 
antibiotics.5 
If a PTC shows a biliary obstruction, one can 
proceed to drain the biliary system percutaneously. 
Percutaneous drainage is designed to relieve biliary 
obstruction and associated jaundice, pruritis, biliary 
sepsis or cholangitis. 11 To achieve drainage, a catheter 
can be placed in the biliary system through to the 
duodenum past the obstruction. These catheters have 
side holes that are positioned above and below the 
obstruction. Endoprostheses, which achieve drainage in 
the same manner but are completely internal, can be 
placed radiologically or endoscopically. The drawback 
to endoscopic stenting is that often the endoscopist 
cannot traverse the stricture. In these cases a rendezvous 
procedure is done where the radiologist places a 
guidewire percutaneously across the stricture into the 
duodenum and the endoscopist then inserts the internal 
stent over this wire. 
Biliary stone removal can also be done 
percutaneously. Both common duct stones and 
intrahepatic duct stones can be removed using basket 
extraction, injected dissolvants and cholangioscopic 
lithotripsy through a percutaneous tract. 15 Transhepatic 
basket extraction and lithotripsy procedures are done in 
two stages with a tract being created by using aT tube, 
allowing this tract to mature for 5-6 weeks and then 
actually removing the stone.15 
In the gallbladder, percutaneous cholecystostomies 
are performed. Indications for cholecystostomy include: 
drainage of purulent material in a patient who is a poor 
surgical risk; unexplained sepsis with an abnormal 
gallbladder on US; to stabilize a patient prior to 
cholecystectomy; or to remove gallstones. 5 Less 
commonly, biliary drainage can be achieved in a patient 
who has a blockage downstream from the cystic duct. 11 
GENITOURINARY INTERVENTIONS 
Just as percutaneous transhepatic cholangiography 
is the initial step in biliary interventions, percutaneous 
nephrostomy (P ) is the initial step in genitourinary 
intervention. The PN can be used to drain the renal 
collecting system in the setting of pyeloureteral 
obstruction or sepsis. It is also used to gain access to the 
collecting system for the placement of ureteral stents or 
to divert urine from the ureters, allowing healing 
following ureteral injury or fistula. 5•11 
In the treatment of renal stones, extracorporeal 
shock wave lithotripsy is the method of choice. In cases 
of large stones or when complications from 
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extracorporeal therapy occur (ureteral obstruction), 
percutaneous intervention is indicated . A P can be 
u ed to debulk large tones prior to lithotripsy and can 
also provide a passage for fragments post lithotripsy." 
Other a pects of renal intervention include biopsy of 
le ion , treatment of cysts or ab ce e and treatment of 
pos t renal transplant complications . All of the e 
indications involve percutaneous methods mentioned 
previously. 
CAVAL AND PORTAL VENO US INTERVENTIONS 
Two procedures which ha ve gained popularity 
recently are percutaneous placement of inferior vena 
cava (IVC) filters and tran sjugular intrahepatic 
portosy temic shunts (TIPS). 
Indications for IVC filters include the patient who is 
refractory to, or has compl ica tions associated w ith , 
anticoagulant therapy and po e a significant r isk of 
d eveloping a pulmonary embolus. The placement of 
these filters percu ta n eous ly is a st raigh tforward 
procedure that can be life saving. A recen t advancement 
is the u e of temporary or retrievable filters which will 
be of benefit to patients with reversible conditions.' 
Transjugular intrahepatic porto ystemic shunts are 
indicated for portal hypertensive haemorrhagic 
complication , intractable a cite and in Budd-Chiari 
syndrome. The procedure involves entering the cava l 
system via the right internal jugular vein and advancing 
a guidewire into a main hepatic vein wi th a small calibre 
ca theter. Then , using a needle advanced over th e 
g uidewire, the portal y tern is punctured 
intrahepatically. The final tage i balloon dilatation of 
the connecting tract and placement of a stent. A major 
problem with TIPS is a stenosis rate of 25% at 6 months 
and about 50% at a year. Thi necessitate routine follow 
up of the tent with Doppler US and revision of the 
procedure if stenosi is found .5·16 
The role of TIPS has yet to be defined. At present it 
is preferentially used in high-ri k patient with variceal 
hemorrhage who are not responding to endoscopic 
clerotherapy. l6 In the future, if long-term patency rates 
a re improved by the use of newer methods, TIPS may 
have an increased role in treating lower risk patients 
that require portal system decompression .16 
CONCLUSION 
In the management of the ill patient that may benefit 
from an interventional procedure, it is important to use 
th e interventionalist as a co ns ultant, much like a 
surgeon . This will allow the determination of the best 
treatment modality for the patient be it medical, surgical 
or interventional. 
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A s we walked into Auditorium A of Univer ity Hospital on that warm September evening, we were not dissimilar to the archetypal Tin 
Woodsman, Cowardly Lion, and Scarecrow from the 
Wizard of Oz. Overwhelmed by looming histology slides, 
anatomy di sections, and pile of textbook , we lacked 
wisdom, heart, and courage, or at least we thought w did. 
Although we were promised a theatrical forum on ethics, 
we were unsure what to expect. What we got was a 
whirlwind tour through what it really means to be a 
doctor. In our constantly changing ociety, a physician can 
not be cold and scientificaUy-rninded, treating his patients 
like problems out of a textbook. Phy icians mu t be caring 
individuals with heightened sensitivity for their patients' 
needs, fears, and expectations of them. They must be able 
to render medical decisions in such a way as to not only 
accommodate patients' medical needs, but to involve them 
as partner in the pursuit of their own health. 
We were introduced to these is ues by watching a 
video of a theatrical, musical performance entitled, "The 
Waiting Room." The entire production, from musical score 
to lyrics, was developed by Western medical students 
under the direction of Dr. Jeff isker, the architect of the 
YeUow Brick Road program. Through song and music, we 
glanced into the lives of three women waiting to see a 
doctor. Each woman, while representing a different 
cultural and temporal framework, was faced by the 
dilemma of physical self-sacrifice in order to fulfill societal 
expectation. The characters featured were a modern-day 
American woman whose desire for physical attractiveness 
prompted breast augmentation and cancer fear, a Chinese 
woman forced by family and cultural tradition to bind her 
feet tightly o she could attract a potential mate, and a 
woman from Victorian England, who wore society's corset 
and was considering oophorectomy to remove mood 
changes and sexual thoughts. What we witnessed was a 
portrait of how health-related decisions can be made in the 
absence of personal choice. 
After the video, Dr . isker shared hi vision of 
creating a dynamic, multimedia forum for the discu sian 
of bioethical and culturally sensitive issue relat d to 
medicine. The goal is to form a program that employs 
pre entations such a plays, literature, theatre and 
narrative seminars to address complex issues that we, as 
students and future practitioners, will face. In the ensuing 
discussion, the class showed a great awareness for the 
importance of ethical decisions and how they shape 
medicine. The term informed consent was left a ide for the 
more appropriate phra e informed choice, a physicians 
should by no means seek to impose their will on patients, 
and simply seek a signature on a consent form. 
Other issues that surfaced for exploration included 
female genital mutilation, a common practice in many 
African countries affecting millions of women. This is an 
example of how cultures can influence per anal health 
by imesh Desai, Dennis Klironomos, and Bindu Kumar 
choice ; women from the e traditions often feel it their 
duty to undergo uch procedures in the name of culturally 
ascribed practice . Understanding the ri ks and benefit of 
a procedure is very important, as cultural factors, gender 
control issues and the undue influence of role models may 
skew patients into making personal decisions that they do 
not want to make. After discussion, we arrived at key 
factors which we felt were essential for an informed choice. 
Patients must be educated about their own health 
concerns, display confidence to make their own choices, be 
independent or free from coercion, and be competent and 
autonomous. With these attributes, patients become 
empowered to make decisions that directly affect their own 
health. It wa acknowledged by the group that it is the 
phy ician's role to provide this empowering atmosphere 
for the patient. 
Linked to the empowerment of the patient is the 
autonomy of the physician, who, as an individual, has the 
ability to refuse to perform a treatment such as genital 
mutilation based on a personal ethical choice. In times of 
conflict, how do physicians express their right to autonomy 
without appearing culturally insensitive or discriminative? 
From the physician's standpoint, an attitude of placing the 
decision firmly in the hands of the patient should be the 
ideal. But, patient autonomy ometimes conflicts with 
social benefit and in these instances it is probably better to 
maintain societal values. For example, a patient requesting 
that her gynaecologist perform a form of female genital 
mutilation should be refused, even though she may then 
proceed to have it done under substandard and potentially 
dangerous conditions. 
Overall, the bioethics seminar was well received . 
Students generally felt that there was a need to bring 
bioethical health issues into discussion o that they could 
begin to think about the complexities of their profession. It 
is important to state that many of the males present felt 
intimidated by the Waiting Room presentation . 
Specifically, they felt that men were portrayed to be the 
sole root of the medical problems that the women faced. 
Since historically men have controlled society ' s 
imperatives, this juxtapo ition is not unreasonable. 
The high level of awareness, cultural sensitivity, and 
analytic ability portrayed by the students outlined the 
lynch-pin of this new method of teaching: as medical 
students passing through a rigorous admissions process, 
we already possess the skills, scientific and humanitarian, 
to become good doctors. Just like the Tin Woodsman, Lion, 
and Scarecrow characters on their journey to Oz, it is 
simply a matter of discovering attributes within ourselves. 
The purpose of the Yellow Brick Road program is to 
maintain and foster our enthusiasm for human i ty , 
compassion, and giving of ourselves to others. These are 
virtues often lo t over a lifetime of board exams and hectic 
call schedules. Our development of clinical skills need not 
interfere with our development as human beings. 
16 
------------------------ U. W. O. Medical Journal 66 (1) 1996 
Ar ti c l e s 
In this way, the Yellow Brick Road represents the next 
tep in advancing medical educa tion . Following the 
innovation of problem-ba ed learning, the interacti e, 
multimedia Yellow Brick Road presentations allow for the 
provocative exchange of ideas regarding the socio-ethical 
aspects of medicine. The active participation of students in 
program design and implementation are instrumental in 
ensuring that each issue becomes incorporated into our 
"databa e" of sensitivity and compassion. The philosophy 
i simple, education through empowerment with bioethical 
tools leads to a life-long awareness of sensitive issues, and 
this leads to better doctors. In the context of this program, 
Western seeks to create a generation of ethically 
responsible physicians. 
As medical chools aero Ontario continually revise 
and redevelop their curricula to embrace the ideals of 
EFPO and produce graduates who are better prepared to 
provide medical service to their communities, the need for 
a program like the Yellow Brick Road becomes apparent. 
In the newly rediscovered era of patient-centred medicine, 
this program attempts to form the student-centred 
curriculum. With sessions already starting to wind their 
way to medical chools across orth America, brick by 
brick, the Yellow Brick Road i charting new territory and 
will certainly be coming to a medical school near you in the 
foreseeable future. Here at We tern, we look forward to the 
upcoming Yellow Brick Road es ions, which will touch on 
a va riety of ethical issues that we, as members of the 
medical community, will surely encounter in the future . 
FAMILY PHYSICIANS URGENTLY NEEDED 
ORANGEVILLE, ONTARIO 
HEADWATERS HEALTH CARE CENTRE, Drangnille is 
urgently seeking family physicians for the Orangeville area. 
n 
Applicants should have an OHIP billing number and be licensed to 
practice in Ontario. 
Headwaters Health Care Centre is a new, fully accredited, 1 DB-
bed, acute-care, well-equipped facility which offers a wide range 
sanOFi WINTHlOP 
A Passion For Life 
in Canada 
A passoon lor R&D More than 30 mmpounds on diNetopment 
., lhe areas ot cardoovascular disease. disease. dosordefs of lhe 
central nen<>us system. osteoporosis. oncology An extensM! 
dinocal researdo program 11 Canada. ll\IOIYing more than 3.500 
pabents in some 80 centres 
A passoon lor strategoc growth In the past year. the addition 
of 19 products to our portfoloo 11 Canada. ondudong many in lhe 
lhe<apeu1ic areas ot rllet.matology. oncology. pain management. 
! sanOft t3W~NnROP ! 
of quality care including Emergency Department, Obstetrics and Critical Care available 24 hours a day. It is served by 37 Family 
Physicians, 30 specialists from 15 disciplines, 5 dental surgeons and supported by more than 400 staff. The hospital will serve a 
catchment area of approximately 90,000 full-time and 10,000 part-time residents. 
Orangeville is a vastly growing rural area situated one half hour north of Brampton. It offers a very attractive quality of We, 
including a new Opera House as well as recreational and educational facilities. It is located less than one hour from major health 
science centres and it is convenient to Toronto, Hamilton and Guelph. Enjoy the advantages of rural living with large city 
accessibility. 
This is a nwanling opportunity Ia deliver exc.Unllarnily practice in a relaxed nand selling. 
Interested applicants should make inquiries or send complete curriculum vitae to Mrs. Nancy Ross, Executive Director, or 
Dr. F. Lindsey, Chair, Department of Family Practice/Emergency Medicine 
Dufferin-Caledon Health Care Corporation, 32 First Street, Orangeville, Ontario, L9W 2E1 . 
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The Basics: A Short Review 
Radiology Paediatric 
of 
The problems diagnosed in paediatric radiology are different from those seen in adult radiology, but the method of reading the paediatric film is 
very similar. An organized approach is the most 
important part of reading films. One approach is 
presented in this article, as well as common problems 
seen on chest, abdominal and bone films. 
TH E PAEDIATRIC CHEST FILM 
One approach to the chest film is the ABC's. Before 
looking at the image, however, look in the corner at the 
patient information. Always make sure that you have 
the correct patient name and the correct date of 
examination. Look at the age of the patient, as certain 
diseases are more common in different age groups . 
Then go on to the ABC's: abdomen, bones (and soft 
tissues) and chest (lungs, airway, mediastinum, 
diaphragm). 
ABDOMEN 
Examine visible abdomen as if you were reading an 
abdominal film (see below). 
BONES AND SOFT TISSUES 
It is easy to overlook these, e pecially if there is a 
glaring abnormality in the lungs. Make sure that all 
normal bony anatomy, (i.e. clavicles, ribs, vertebrae) 
are present. Look for abnormal structure, fractures, and 
destruction of bone. The spinous processes of the 
vertebrae are not fused in children under three. Next, 
look for swelling, foreign bodies, and calcifications in 
the oft tissues of the neck, thorax, limbs and abdomen. 
Beware of artifacts such as clothing, jewelry and skin 
folds. 
CHEST 
1. Airway: This should be visible in all chest films, 
from below the nasopharynx to the carina (the division 
of the trachea into the right and left bronchi). Evaluate 
for patency, position and size. The trachea normally 
buckles during expiration in infants. Look for 
consistent narrowing of the airway, as this may be a 
clue to extra tracheal masses and vascular rings, as well 
as tracheal abnormalities. A steeple appearance of the 
subglottic airway on inspiration, in addition to stridor 
and a barking cough, is pathognomonic for croup. A 
thumb-like opacity on lateral views of the upper 
airways is seen in epiglottitis. However, this diagnosis 
should be made clinically; the airway may occlude in 
by Nicole S. Isaac, Meds '97 
Douglas J. Moote, MD, FRCPC 
the time that it takes to radiograph the patient. The 
trachea lies to the right of the midline. Deviation from 
this position is an important clue to mediastinal 
masses as well as differences in hemithoracic pressure. 
ote the position of the major bronchi. 
2. Mediastinum: This is a difficult part of the 
paediatric chest x-ray, primarily because the thymus 
obliterates many structures from view. Additionally, 
because of the fast respiratory rate and inability of the 
infant to cooperate, it is difficult to get an inspiratory 
film. Look for position, size and contour of the 
mediastinal structures. The thymus has a wavy 
contour and may extend from the thoracic inlet to the 
diaphragms. It can obscure the lung fields. It should 
not alter the position of any structures in the chest. 
3. Heart: The heart is situated mainly in the left 
hemithorax. It is difficult to evaluate the heart size on 
the frontal film because it is not necessarily taken 
during inspiration. On the lateral film, draw a line 
from the carina straight down to the diaphragm. This 
line will intersect an enlarged heart. An enlarged heart 
will push adjacent structures such as the carina 
posteriorly . It may indicate congenital heart disease. 
Tetralogy of Fallot (overriding aorta, right ventricular 
hypertrophy, right ventricular outflow tract 
obstruction & ventricular septal defect) causes a boot 
shaped heart. 
Figure 1: A 7-year-old boy wit II a cli11ical history of p11eumorria. Note tile atr space 
disease i11 tl1e rigllt lower lobe witll a11 air fluid level. Tllis hmg abscess resolt'<'CI witll 
treatment. 
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Figure 2: Tl1e child i11 this film i11ha/ed a pen11ut wl1ich lodged in the left mninstem bronc/ms. Subtle abllon11alities exist 011 all inspiratory film, but with expiratio11 , tl~e contrast beht>eell 
the 11ormnl collapsi11g rigllt hmg a11d the left lung wl1ich is trappi11g air due obstn1dio11 by the pea1111t is more 11oticeable. 
4. Great Yes els: The aortic arch and descending 
aorta hould be on the left of the midline. Also look for 
the left and right pulmonary arteries situated in the 
lung hila. 
5. Esophagus: This is po terior to the trachea. 
Esophageal air may be normal in the neonate, but is 
abnormal in older infant and children. 
6. Lymph odes: In pathologic conditions such as 
lymphoma, lymph nodes may be visible in the hilar 
regions of the chest. 
7. Lungs: The lungs are the largest and most 
exciting structure seen on the chest x-ray. There are 
two fi ures in the right lung and one in the left lung. 
Look for any invasive tubes or monitoring equipment 
that may hint at the diagnosis or ymptoms, and ensure 
that the lines are correctly placed. The left hilum is 
s lightly higher than the right hilum, and the right 
hemidiaphragm is slightly higher than the left . A 
change in this anatomy is frequently pathologic. The 
heart borders should be harply defined by the air in 
the lung . Fuzzy or obscured borders indicate lung 
abnormalitie uch as pneumonia, abscess (fig 1), or 
atelecta is. Atelectasis results in a decrease in volume 
of the affected lung, and adjacent fissures will be 
pulled toward the affected area . Consolidation will not 
change the lung volume. The location of consolida ted 
lung can be pinpointed by the di appearance of normal 
anatomy (i.e., the diaphragms are obscured by lower 
lobe pathology, the left heart border is obscured by 
lingular pathology, the right lower heart border by 
right middle lobe pathology and the upper h eart 
borders by upper lobe pathology). The costophrenic 
angle hould be sharp. Rounded angles indicate 
pleural fluid or thickening . Lung markings (white 
lines created by bronchi and va culature) should be 
most vi ible in the proximal 2 / 3 of the lung. If a 
pneumothorax is pre ent, there will be no vascular 
markings surrounding the collap ed lung and the 
perimeter of the lung can be visualized. This is be t 
Figure 3: Ultrasound of appendicitis. Ultrasound is used whm tl1e cli11ica/ history is 
equit>aca/ in suspected appmdicitis. This appendix l10s thickened walls and a r•i>ible 
calcification. Tl1e stone is echogenic (white)(/ong arrow) a11d casts a l1ypoec/10ic (black) 
shadow (small arrows) behi11d it. 
20 
------------------------- U. W .O. Medical Journal 66 (1) 1996 
Figure 4: A newbom child with failure to pass meconium and obstruction on abdominal 
radiographs (not included). Note the narrowed rectum (arrowheads) which represeuts the 
aganglionic segment in this patien t with Hirsclzsprung's disease. The dilated bowel (curoed 
arrows) is histologically normal 
Figure 5: U/trasouud of a 4-week-old boy with a 2-week history of projectile vomiting. 
The pylorus is elongated, with thickened muscular walls (arrows) and a stenotic canal 
(curoed arrow). The pylorus starts to curoe with iucreasing size. 
F ea t u r e Sec ti o n 
seen on expiratory films because decreased aeration 
makes the lung denser (whiter) compared to black 
pleural air. Expiratory films are also useful to look for 
air trapping in foreign body aspiration (fig 2). Other, 
more subtle lung field abnormalities include 
respiratory distress syndrome (RDS) and neonatal 
pneumonia, which often mimics RDS. The lung fields 
are small, hazy, with a reticular (net-like) pattern 
caused by interstitial fluid and atelectasis, and there 
are dilated bronchi. The pattern with neonatal 
pneumonia is slightly coarser, with better lung 
expansion and pleural effusions. 
THE PAEDIATRIC ABDOMINAL FILM 
An orderly approach, similar to that used for the 
chest film, should be used for the abdominal film. 
There should be two views of the paediatric abdomen: 
supine and erect (or decubitus), as well as a frontal 
chest x-ray. 
CHEST 
Carefully review any visible chest. 
BONES AND SOFT TISSUES 
Look at the ribs and pelvis for fractures and 
dysmorphism. Ensure that the spinal column has a 
normal contour, particularly in the older child who 
may have scoliosis . Watch for areas of decreased 
density in the bone which might signal malignancy, but 
do not be fooled by overlying bowel gas. Look for the 
properitoneal fat line (flank stripe) on the supine film. 
It indicates the edge of the peritoneal cavity and will 
disappear if edematous (peritoneal inflammation). If 
the colon is gas filled, it should abut the flank stripe. 
Space between the two may be due to peritoneal fluid 
or a solid mass. 
ABDOMEN 
Free peritoneal air is always abnormal. It can be 
seen below the diaphragm and above the liver and 
stomach bubble on an erect film. If there are only small 
amounts of air, it may be easier to see it on a left lateral 
decubitus film as a thin line above the liver. A 'football 
s ign" ma y be seen; the lace of the football is the 
falciform ligament (normally invisible) highlighted by 
a football-shaped lucency of free air. The kidneys are 
10-12 em long and located at the Tl2-L2 level, the right 
being slightly lower than the left. Their outlines can be 
seen faintly on either side of the iliopsoas shadows. It 
is important to look for stones and other calcifications 
in the kidneys and along the path of the ureters as well 
as in other areas of the abdomen. Decide where the 
calcification is and determine its character. Ill-defined 
margins, irregular outline, and punctate calcifications 
are ominous signs, possibly indicative of malignant 
neoplasm. An appendicolith may appear in the right 
lower quadrant as a cause for appendicitis. In clinically 
obscure cases, appendicitis ma y be diagnosed b y 
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Figure 6: Tltis clrild rmderwenl a slcelrtal survey for suspected cltild abuse, wlticlr consists of frontal and lateral skull, frontal and lateral spine, fron tal cites/, and upper and lower 
extremity radiographs. Along witlt multiple rib and radial and ulnar fractures, tire clti/d tl!tlS found to ltave bilateral bucket lumdle and comer fractures (s /raiglrl amnDS), and periosteal 
reaction (curved arrows) of bollr tibiae and femora as well as a posteriorly displaced tibia wit It respect to its epiphysis (open a"ow). 
ultrasound. A thickened appendiceal wall +I - an 
appendicolith will be seen (fig 3). Examining the bowel 
gas pattern is a n important part of abdominal 
radiographic evaluation. Look at the position, contour 
and size of the gas pattern. The large bowel frames the 
peritoneal cavity, with the small bowel situated centrally. 
In infants, this may be the only clue to distinguishing 
small from large bowel. The caecum, which has a larger 
diameter than the rest of the bowel, should be in the 
right lower quadrant. Displacement may be due to 
malrotation of the gut. Make sure that the gastric bubble 
is under the left hemid.iaphragm for similar reasons. The 
bowel walls, highlighted by air within the lumen, should 
be smooth and regular. Irregularity may denote 
inflammation from diseases such as Crohn's disease, 
which has a cobblestone appearance. Physiologically, 
there should be less than three air fluid levels. There are 
occasionally more in infants and young children. These 
show up as menisci between the black (hypodense) air 
and the white (opaque, den e) fluid . Multiple air fluid 
levels may denote mechanical obstruction such as 
volvulus or Hirschsprung 's disease (colonic 
aganglionosis) (fig 4). The double bubble sign (2 air-filled 
adjacent areas of bowel) is seen with proximal 
obstruction such as duodenal atresia. If a mechanical 
obstruction has been present for some time, bowel distal 
to the obstruction will be devoid of air. A paralytic ileus 
is identified by dilated loops of bowel. A single loop of 
dilated bowel is called a "sentinel loop" and is associated 
with disease of a specific organ in a localized area, such 
as in pancreatitis. Pyloric stenosis is not diagnosed on 
plain film, however, the stenotic pylorus is visible with 
ultrasound (fig 5). 
THE PAEDIATRIC SKELETAL FILM 
As with other types of films, approach the bone 
film methodically. Always get at least two views; the 
cortex is circumferential, while the plain film presents 
only a 2-dimensional view. 
Look at the soft tissues, joint space and bone. Long 
bones, such as the femur, have four parts. The 
diaphysis is the shaft. The metaphysis, at the ends of 
the diaphysis, is attached to the epiphyseal pla te. The 
epiphysis ar ticulates in the joint. Bone age can be 
approximated by comparing hand and wrist x-rays to 
those in an atlas. Different epiphyses ossify (become 
roentgenographically visible) at different ages. 
Observe the alignment of the bones. Malalignment 
of the bones with respect to each o ther may indicate 
dislocation. Bone densi ty is difficult to estimate on 
plain film due to differences in film exposure, but 
asymmetry or inconsistency within a bone may 
indicate a lytic process. Look at the continuity of the 
bony cortex and the trabecular pattern. Children's 
bones are more flexible than adult's, and a slight 
cortical or trabecular discontinuity may be the only 
sign of fracture. The greenstick fracture is manifested by 
a bowing of a long bone with a discon tinuity of the 
cortex (the fracture) on the convexity. Buckling of the 
cortex is seen in a torus fracture . The periosteum (the 
metabolically active covering of long bones) is not 
normally seen except in 2-6 month old infants. A 
visible perios teum indicates periosteal reaction to 
trauma. It is loosely applied to the paediatric diaphysis 
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ASTRA continues to lead the fight against peptic 
ulcer disease with research and development 
of new therapeutic strategies for effectively 
erad icating H. pylori. 
For more information about the latest 
developments in H. pylori eradication, please 
call 1-800-668-6000, extension 6124, 
to speak with a Medical Information Specialist 
from Astra. Your partner in conquering the 
acid and H. pylori. 
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and with trauma, it can be lifted off the bone. It will 
then form a thick layer of new bone within 7-14 days. 
This reaction can be u sed to date a fracture . The 
periosteum is more tightly applied to the metaphysis. 
A twisting injury can cause corner and bucket handle 
f ractures - a thin wedge of bone is torn from the rim of 
the metaphysis and resembles a corner of bone torn off 
or the handle of a bucket (Fig 6) . Multiple fractures at 
different stages of healing, rib, corner and bucket 
handle fractures are virtually pathognomonic for child 
abuse. Fractures that involve the physis are classified 
under the Salter-Harris classification . 
All fractures should be described with respect to 
type (open or closed), site, pa ttern (transverse v s. 
spiral, compression vs. greenstick; fragmentation) , and 
displacemen t (apposition, angulation, rotation and 
length) . Some fractures such as supracondylar (elbow) 
fractures are difficult to see on plain film. A clue to 
their existence is elevation of the articular fat pads -
the sail sign. The lucent fat pad resembles a sail on the 
distal humeral metaphysis. 
Developmental dysplasia of the hip is a common 
problem best seen with sonography because the hip joint 
is not fully ossified in infants. The acetabulum appears 
flat instead of being cupped to fit the femoral head. 
Scotlabank 
J!l8lr" ® 
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The most important thing to remember about 
reading paediatric radiographs is to do so 
methodically. Knowledge of the pathology and clinical 
progression of a disease will help in the identification 
of pertinent radiologic signs. 
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0/anzapine ''' Novel antipsychotic power for routine use 
ZVPREXA• (olanzapine tablets) 
THERAPEUTIC CLA S SIFICATION - Antipsycholic Agent 
P HA R MACOLOGY 
Pharmacodynamic Properties: ZVPREXA" (oianzapine). a thH!OObenzodiazepine, IS an anb· 
psychotic agent, dosplaying high receptor affinity binding In vitro at serotonin 5-HT.,.., 
(Ki = 4 and 11 nM, respectively) , dopamine D, , D2, D,. D, (Ki = 11·31 nM), muscarinic M, .. (Ki = 1.9-2.5 nM). adrenergic tt,(Ki = 19 nM), and histamine H, (Ki = 7 nM) receptors. In a behav· 
10011 paradigm predicbve of antipsycholic actMty, oianzapine reduced conditioned avoidance 
response on rats at doses lower than 4 times those requored lo produce catalepsy. In a single dose 
( 10 mg) PET study in healthy subjects, oianzapone produced higher 5-HT 20 than dopamone D2 
receptor occupancy The percent of D2 occtJpancy was less than the threshold value predictive of 
extrapyramodal events. 
PhannacoklneUc Properties: ZVPREXA IS well absorbed alter oral adrmniStration. reachong peak 
plasma concentrations within 5 to 8 hours. The absorption is not affected by food. Plasma con· 
centrations of orally administered oianzapine were linear and dose proportional in trials studying 
doses from 1 to 15 mg. The maxmum plasma concentrations (Cmax) of oianzapine after songle 
oral doses ol5, 10 and 15 mg averaged 7, 14, and 21 nglml. respecllvely (20 nglmL = 0.064~tM). 
In young healthy volunteers, after once-a-day repealed dosing, steady-state Cmax was appro.,. 
mately twoce that achoeved after a single dose (eg. 23 ng/mL versus 12 ng/mL for a tQ.mg dose) 
In the elderly, the steady state plasma concentration was approximately 3-fold higher than that 
achoeved after a single dose (e.g. 16 ng/mL versus 5 ng/mL for a 5-mg dose). In both, young and 
elderly, steady-stale concentrations of oianzapone were obtaoned after seven days of once 
daily dosing. 
Over ume and dosage range, pharmacol<ineloc parameters withon an ondividual are very con-
sostent However. plasma concentrations, half-life and clearance of oianzapine may vary between 
individuals on the basis of smol<ing status, gender, and age (see Special Populations). Data from 
pooled, single dose pharmacokinetic studies showed the half-lne of oianzapine to range from 
21 to 54 hours (5th to 95th percentile). and the apparent plasma clearance lo range from 12 to 
47 Uhr (5th to 95th percentile). 
The plasma proteon binding of oianzapine was about 93'l. over the concentration range of about 
7 lo about 1000 ng/mL Olanzapine is bound predominantly to albumin and a, ·acid glyco-
proteon. Olanz.apone os metabolized in the live< by COOfU98bve and oxodai!Ve pathways. A mass 
balance study showed thai approximately 57% of radiolabeled oianzapine appeared in unne, 
pnncopally as metaboiHes. The major circulating metaboiHe is the 1Q-Nijlucuronide. which is phar· 
macologocally onaciJve and does not pass the blood brain barrier. Cytochromes P4so-GYP1A2 and 
P4so-GYP206 contribute to the formation of the N-desrnelhyl and 2-hydroxymelhyl metaboiHes, 
respectJvely. These metabo!Hes do not produce behavioural activrty in the rat at doses 4 to 
16 bmes greater than active doses of oianzapone. 
In vitro mocrosomal studies show thai oianzapone IS a weak inhibotor of CYPt A2 (Ki = 36 ~tM) . 
CYP206 (Ki = 89 ~tM), and CYP3A4 (Ki = 490 ~tM) . Based upon these Ki values, rottte onhibobon 
of these cytochrome P-450 enzymes is expected "' vwo at concentrations below 5 11M (roughly 
1500 nglmL) because the oianzapine concentration will be less than 10% of its Ki value. 
In clinical studies, observed steady-state plasma concentrations of oianzapine are rarely 
> t 50 ng/mL (approximately 0.5 11M). Olanzapine IS thus not likely to cause clinically important 
pharmacokinetic drug-drug interactions mediated through the metabolic routes outlined above 
(see PRECAUTIONS, Drug Interactions). 
Special PopulaUons: In a single dose study onvolvong 24 healthy subjects the mean elimonabon 
=.e t!'tow~ was prolonged in elderly subfects compared with non-<>lderly subjects. as 
<65 years 
(N=B) 
2:65 years 
(N:16) 
Men 29 hours 49 hours 
Women 39 hours 55 hours 
Large scale population pharmacokinetic analyses show that the plasma clearance of oianzapone 
IS lower on elderly versus young subjects, on females versus males, and in non-smokers 
versus smokers. However, the overal variabiiHy between individuals is larger than the magnitude o1 
mpact of the ondivodual factors of age, gender or smokong. on oianzapine clearance and half .life 
The pharmacokoneuc characteristics of oianzapone (5 mg single dose) were not sOOslantJalty 
different in patients with severe renal impaorment and on nonnal subjects. Muftipte-dose 
studies in pauents wrth renal failure, however, have not been performed. 
No differences on the single-dose pharmacokinetics of oianzapine were noted in subjects woth 
cfonocaUy signifocant cirrhosis (who were mcost1y smokers) when compared to healthy subjects (all 
non-smokers). Multiple-dose studies in patients woth hepatiC ompairment, however, have not been 
performed. 
No specofoc pharmacokinetic study was conducted to onvestigate ethnicity effects, but a revoew 
of the climcal pharmacology studies identifoed no omportant differences on the disposition of olan-
zapone on Gaucasoan subjects versus subjects of Afncan descent. 
C LINICAL TRIALS 
The efficaocy of ZVPAEXA" (olanzapine) in the redUCtion of and maintenance of the reduction of the 
manofestations of schozophrenia and related psychobc disorders was established in 3, well-ron-
trolled clinicallrials of psychotic inpatients who, al entry mel the DSM·III·R cmeria for schizophre-
noa (most with a course at entry ol "chronic with arute exacerbation") and 1 welk:ontrolled c1onoca1 
tna1 of psychotoc inpatients and outpatients who, at entry, mel the DSM-III·R cmeria lor sctuz<>-
phrenoa. schozophrennorm disorder, or schozoalteci!Ve diso<der. The results of the trials lollow: 
(1) A 6-week, placebo-controllrial (N:335) compared 3 fixed dosage ranges of ZVPREXA 
(5% 2.5, tO% 2.5, and 15% 2.5 mglday 00), 1 dosage range of haloperidol (15 ± 5 mglday on a 
BID schedule), and placebo. The 2 higher dosage ranges o1 ZVPREXA were statistically sognm-
cantly supenor to placebo on the Brief Psychiatric Rating Scale (BPRS) total. the Clinical Global 
Impressions • Severity of Illness (CGI·S) scale, and the SPAS positive psychosis cluster. The 
hoghest dosage range of ZVPREXA was statistically signnicantly superior to placebo and to 
haloperidol on the Scale for the Assessment of Negative Symptoms (SANS). Effocacy of ZVPREXA 
generally increased wrth dose. The 5 ± 2.5 mglday dosage range of ZVPREXA was numerically, 
but not statistically, signnicantly superior to placebo on SPAS total and other assessments of over· 
aN psychopathology. 
(2) A 6-week, placebo-controled lrial (N= 152) compared 2 foxed doses of ZVPREXA ( 1 or 
10 mglday OD) and placebo, ZVPREXA, 10 mg/day, was statisticaDy signnicantly superior to place-
bo on the SPAS total, the BPRS positive psychoSis cluster, the CGI-S scale, the POSitive and 
Negabve Syndrome Scale (PANSS) total, the PANSS positive subscale, and the PANSS negative 
subscale. ZVPREXA, 1 mglday, appeared to be a ne>-effect dose with no difference, clinically or 
statJstically, from placebo on any assessment of psychopathology. 
(3) A 6-week. dose comparison lrial (N=431) compared 3 fixed dosage ranges of ZVPREXA 
(5 ± 2.5, 10 ± 2.5 and 15 ± 2.5 mg/day 00), ZVPREXA (1 mg/day OD). and haloperidol (15 ± 
5 mglday on a BID schedule). There were no statJstically significant differences between groups on 
efficaocy measures except for the highest dosage range of ZVPREXA. which was statistocally 
significantly superior lo ZVPREXA, 1 mg. on the BPRS positive psychoSis cluster, PANSS posrtove 
subscale, and the CGI·S scale. 
(4) A 6-week comparator-rontrolled lnal (N=1996, 2:1 randomization, ZVPAEXA : haloperidol) 
compared 1 dosage range of ZVPREXA (5 to 20 mglday OD) and 1 dosage range of haloperidol 
(5 lo 20 mg/day OD). The arute mean modal doses (for those patients with al least 3 weeks of 
treatment) were 13.2 mg/day for ZVPREXA and 11.8 mglday for haloperidol. ZVPAEXA was 
statistocally signtficantly superior lo haloperidol on the BPRS total, the BPRS negative psychosis 
cluster. the PANSS negative subscale, and the CGI·S scale. ZVPREXA was also stabstoc:ally 
sogrnficantly supenor to haloperidol on the Montgomery·Asberg Depression Rating Scale 
(MAOAS). The validHy of this scale in patients With schizophrenia. hoWeVer, Is not established 
(5) The effeci!Veness of ZVPREXA on long-term therapy, o.e., >6 weeks, was evaluated in 
3 double-blind. controlled, extension maontenance trials (of arutelrials 1, 3, and 4 above). Patients 
who showed adequate clinical improvement following double-blind arute therapy were allowed to 
contonue on "' a double-blind, long-term extensoon mamlenance phase on their arute dosage 
regome. Long-term maintenance of treatment response (as defined by continued reduction n sogns 
and symptoms sufficient to not requore hospitafozation for psychosis) was compared over tJme 
(894 ZVPAEXA·treated patients; median length ol treatment was 237 days). The percentage of 
patients maintaln1ng treatment response over one year was compared. ZVPREXA was statistically 
sognificantly superior to placebo on the one placebo-controlled lnal and was comparable or sta· 
bstically sognifocanlly superior to the active comparator in 3 of 3 actiVe comparator-rontrolled trials. 
While the effocecy of ZVPAEXA at a dose of 5 mg/day was not statistically superior to placebo 
(see (1)) , some individual patients receiving this dose had a good acute response, and were well 
maintained during a one year extension phase. 
The above trials (including open-label extension) and an additional lrial in geriatric patients with 
pnmary degenerative dementia of the Alzhetmer's type constHute the primary database (N:2500 
patients treated with ZVPREXA, corresponding to 1122.2 patient-years; N=810 patients treated 
with haloperidol, corresponding 1o 193.0 patient-years; N:236 patients treated with placebo, 
corresponding to 27.1 patient-years). 
INDICATIONS AND CLINIC A L USES 
ZVPREXA" (oianzapone) is indicated for the arute and maintenance treatment of schizophrenia 
and related psychotoc disorders. In controlled clinical tnals, ZVPREXA was found to improve both 
positive and negabve symptoms. 
ZVPREXA has been shown to be effeci!Ve n mantainong clinical improvement dumg one year 
of contnuabon therapy in patients who had shown an onitlallreatmenl response. 
CONTRA IN Dl CATIONS 
ZVPREXA• (oianzapone) is contraindicated on those patients with a known hypersensotivrty to the 
drug or the excipoenls of the product 
WARNINGS 
Neuroleptic Malignant Syndrome: In prernarl<eting cfoniCBI tnals there were no reported cases of 
NMS in patients receiving ZVPREXA• (olanzapine). However, NMS is a potentially fatal symptom 
complex, that has been reported in assoaation with antipsychotic drugs. Clinical mandestations 
of NMS are hyperpyrexia, muscle ngodrty, altered mental status. and evidence of autonomic 
onstabiloty Qrregular pulse or blood pressure, tachycardoa, diaphoresis, and cardiac dysrhyth-
moa). Addotoonal signs may include elevated creatone phosphokinase, myoglobinuria 
(rhabdomyolysls), and arute renal failure. 
The management of NMS should onclude ommediate disconlonualoon of all antipsychotic drugs 
including ZVPREXA. intensive monHonng of symptoms and treatment of any associated medical 
problems. There IS no general agreement about specific pharmacologicaJ treatment for NMS. 
If a patient requores antipsycholic drug treatment alter recovery from NMS, the reintroduction of 
therapy should be very carefully consodered, sonce recurrence of NMS has been reported 
Tardive Dyskinesia: Tardive dyskinesia (TO). a syndrome consisting of potenlialy orreversible 
onvoluntary dysloneuc movements, os assoaaled with the use of antipsychotic drugs. Tardive dys· 
kones4a occtJrs more frequently in elderly patients, hoWeVer. patients of any age can be affected. n 
IS unl<nown whether antipsychotic drugs may differ in theor potential to cause TO. However, dunng 
long-term, double-blind extension maonlenance trials (894 olanzapine-lreated patients; median 
oianzapine treatment. 237 days). ZVPAEXA was associated with a statistically signifocantly lower 
oncodence of treatment emergent dyskonesoa compared to haloperidol. 
The risk of developing tardive dyskinesia and the chance of H beoorning irreversible, are 
believed lo oncrease as the duration of treatment and the cumulatrve dose of antipsychotic drugs 
oncrease. However, the syndrome can develop, although less commonly, alter relatively brief 
penods of treatment at low doses. There is no known treatment for established cases ol TO. The 
syndrome may rernrt, partially or completely, d antipsycholic drug treatment is withdrawn. 
Anbpsychotic drug treatment itself, however, may suppress the signs and symptoms of tardiVe 
dyskonesoa, thereby maskong the underlying process. 
Given these considerations, ZVPREXA should be prescnbed "' a manner that is most likely to 
monimoze the risk of tardive dyskinesia. As with any antipsychotic drug, ZVPREXA should be 
reserved for patients who appear to be receivong substanUal benefit from the drug. In such patients 
the lowest effeci!Ve dose and the shortest duration of treatment should be sought The need for 
contonued treatment shotAd be reassessed periodically. 
If sogns or symptoms of tardive dyskines4a appear on a patient on ZVPAEXA, drug discontnua· 
bon should be considered. However, some patients may benefit from continued treatment with 
ZVPREXA desprte the presence of the syndrome. 
PRECAUTIONS 
Lactose: ZVPREXA• (oianzapine) tablets contain lactose. 
Potential Effect on Cognitive and Motor Performance: Because ZVPREXA may cause 
somnolence, patients should be cautioned about operating hazardous machinery, including motor 
vehiCles, until they are reasonably certaon thai ZVPREXA therapy does not affect them adversely. 
Hypotens ion and Syncope: As wrth other drugs thai have high alpha· t adrenergic receptor 
blockong actMty, ZVPREXA may onduce orthostatic hypotension, tachycardia, dizziness, and 
somebmes syncope, especial!) at the onotoabon of treatment In a clinical trial database of 2500 
patients treated with ZVPREXA. syncope was reported in 0.6% (1512500). The risk of orthostatic 
hypotensoon and syncope may be mnmozed by initialing therapy with 5 mg OD (see DOSAGE 
AND ADMINISTRATION). A more gradual titration to the target dose should be considered n 
hypotensoon occtJrs. ZVPAEXA should be used with particular caution in patients with known car-
diovascular disease (history of myocardial onfarction or ischernoa, heart tailure, or c:onduciJon 
abnormalities) , cerebrovascular disease, and condHions which would predispose patients to 
hypotensoon (dehydration, hypovolemoa, and treatment wrth anbhypertensive medications). 
Seizures: Conventional neurolepbcs are known lo lower seozure threshold. In clirucal tnals, 
seozures have occtJrred in a small number (0.~. 2212500) of ZVPREXA-trealed patients. There 
were confooodong factors that may have contributed to the occtJrrence of seizures in many of these 
cases. ZVPAEXA should be used cautoously on patients who have a history of seizures or have 
condHions associated with seizure or have a lowered seizure threshold. 
Transaminase ElevaUons: During prernarl<eting clinicallrials, therapy with ZVPAEXA was asso-
coated with elevation of hepatic transamonases, primarily ALT (SGPT). Within a clinicallrial data· 
base of 2280 ZVPAEXA·trea1ed patients, wrth baseline ALT (SGPT) levels $60 IUA., 5.9% 
(t3412280) had treatment-emergent ALT (SGPT) elevations to >120 lUll, 1.9% (4412280) had 
elevations to >200 lUll, and 0.2% (512280) had elevaticons to >400 lUlL No patien1s had 
values on exoess of 700 lUlL None of the ZVPREXA·treated patients who had elevated lrarosam· 
inase values manifested clinical symptomatology associated with liver impairment The maJOrity 
of trarosaminase elevations were seen dunng the first six weeks of lrealrnenl. Most elevations were 
tranSient (66%) while patients continued on ZVPREXA therapy, or falling (11%) at the last avail-
able measurement. Of the 134 ZVPREXA·Ireated patients whose enzyme levels increased to 
>120 lUll, 20 discontinued treatment (6 for hepatic, 14 for other reasons) while their ALT (SGPT) 
values were stil nsing. In 38 ZVPREXA·Ireated patients woth baseline ALT (SGPT) >90 lUll, none 
experienced an elevation to >400 lUlL 
. Precauboros should be exerased when usong ZVPREXA on patients with prlH!Xlsting hepatic 
disorders. on patients who are betng treated wrth potentJalty hepatotoxic drugs, or n treatment· 
emergent sogns or symptoms of hepabc ompaorment appear. 
"FICtitious case, may not be predictive of results in other patients. 
Martin has schizophrenia. And 
egistered trademart ol Eli Lilly and Company; used under license . 
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Introducing PrZyprexa· (olanzapine), 
Making Re-integration the Goal ... 
ulfilled desire to be back home.* 
When your goal is Re-integration ... 
Choose Zyprexa 
Novel antipsychotic power for routine use in 
the majority of patients with schizophrenia and 
related psychoses 
Zyprexa ... 
• compared to haloperidol offers superior efficacy in acute and 
maintenance treatment in both positive and negative symptomst 
• is generally safe and well-tolerated§ 
• offers convenient once-daily dosing at 1 0 mg* 
You and your patients measure success one achievement at a 
time. Progress may be modest or great, but every achievement 
is counted as a victory toward the goal of re-integration. 
t6 week acute phase: Zyprexa (n=1 ,312), 5-20 mglday; Haloperidol (0=636), 5·20 mglday; SPAS Total score p:0015: PANSS polilve 
score p:0.056; PANSS negative score p:0.032. Kaplan-Meier survival curve at 1 year: Zyprexa (n><627), 2.5-20 '"9'day; 
Haloperidol (n=180), 5-20 mglday, p:0.034. 
§The most common adverse events associated with Zyprexa are dizziness, consbpabon, AlT(SGPT) onct81188d, M1911 gain, lllc8llilla, 
and postural hypotension. Caution should be exercised in patients With renal and/or hepabc ornpamnent. 
tlncrease to doses greater lhan target dose only after clinocal assessment The safety of doses alxNe 20 '"9'day has na1 t..1 
evaluated tn clinical tnals. Responding patients should be conbnued at the lowest dose Meded 1o - rwnill8ion. 
0/anzapine 
..,.,lr;;;;• antipsychotic power for,... 
For patients who have known or suspected abnormal hepatic function prior to starting 
ZVPREXA. standard clinical assessment, including measurement of transaminase levels is rec· 
ommended. Periodic clinical reassessment with transaminase levels is recommended for sucl1 
patients, as well as for patients who develop any signs and symptoms suggestive of a new onset 
liver disorder during ZVPREXA therapy. 
Hematologic Indices: In clinical trials, there were no data to suggest ZVPREXA adversely affect· 
ed bone marrow function. even in patients with a hiStory of clozapone-associated neutropenia 
or leukopenia ZVPREXA was associated With a 5.7". ltiCidence of mainly transient treatment· 
emergent elevabons of eosinophil counts above the normal range. Elevations were not associat· 
ed With any symptoms, identifiable allergic phenomena. or changes 1n other hematologic indices. 
Hyperprofactinemla: As with other diUQS that block doparTwle 02, and/or serotonin 5-HT2 recep-
tors, olanzapine may elevate prolactin levels. Elevabons assoaated with ZVPREXA treatment are 
generally mild, and may decline during continued admonlstrabon. 
Since tissue culture experiments indicate that approximately one third of human breast cancers 
are prolactin dependent in llitro, ZVPREXA should only be administered to patients with previously 
detected breast cancer ~ the benefits outweigh the potential risks. cautJon should also be exer-
cised when considering ZVPREXA treatment " pat1811ts With poturtary turnors. Possible manifests· 
lions assoaated with elevated prolactin levels are amenormea, galactorrhea, and menoohagl8. 
As is common with compounds which stimulate prolacbn release, the administration of olan-
zapine resutted "' an increase in the incidence of mammary neoplasms "' bolh rats and mice. The 
physiological differences between rats and humans with regard to prolactin make the clinical sig· 
ntlicance of these findings unclear. To date. neither clinical nor epidemiologocal studies have shown 
an associabon between chronic administration of these diUQS and mammary tumorigenesis. 
Uric Acid: In the premarketing clinical trial database, ZVPREXA was associated with mild eleva· 
lions of unc acid "' some patients. However, only 1 ZVPREXA-treated patient experienced treat· 
ment-emergent gout, and the baseline uric acid concentration for this patient was at least as large 
as att concentrations observed while the patient was rec:eMlg ZVPREXA 
Weight Gain: Olanzapine was associated with weight gam dunng clirucal trials. Patients treated at 
higher doses ( 15 ± 2.5 mglday) had the greatest mean weight Qalll. However, a categorization 
of patients at baseline on the basis of body mass Index (BMI) revealed a significantly greater 
effect in patients with low BMI compared to normal or overweight patients. Using pooled data 
from patients treated with olanzapine over the dosage range of 5 mg to 20 mg per day, weoght gain 
tended to level off at 6 to 8 months of treatment. With a mean gam of 5.4 kg. 
Antiemetic Effect: Consistent with its dopam111e antagonost effects, olanzapine may have an 
antiemetic effect. Such an effect may mask signs of toxicity due to overdosage of other drugs, or 
may mask symptoms of disease suc11 as brain tumor or intestinal obstnuction. 
Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature 
has been attributed to antipsychotic agents. Appropriate care is advised when prescribing 
ZVPREXA for patients who wil be experiencing conditions whiCh may contribute to an elevation of 
core temperature, eg. exercising strenuously, exposure to extreme heat, receiving concomitant 
medicat100 with anticholinergic activity, or belllQ SlJbtecl to dehydrabon. 
Suicide: The possibility of suicide or attempted suiCide os A1herent in psychosis, and thus close 
supervision and appropriate clinical mar13gement of hogh-nsk patients should accompany drug 
therapy. 
Drug Interactions: Given the primary CNS effects of ZVPREXA, caution should be used when H is 
taken in combination with other centraUy-acllng diUQS and alcohol. As rt exhibits m vrtro dopa· 
mine antagonism, ZVPREXA may antagonize the effects of levodopa and dopamine agonists. 
Because of its potential for Inducing hypotensoon. olanzapone may enhance the effects of certain 
antihyperterosive agents. 
Poterrtial for Other DNQS to Affect ZVPREXA: The metabolism of olanzapine may be induced by 
concomHant smoking, or carbamazepine therapy. The concomitant administration of actiVated 
charcoal reduced tha oral bioavailabiiHy of ZVPREXA by 50'lo to 60%. Single doses of antacid (alu· 
minium, magnesium) or cimetidine did not affect the oral bioavailabiiHy of ZVPREXA. Agents that 
induce CYP 1 A2 sucl1 as omeprazole may increase clearance of olanzapine. Conversely, inhibitors 
of CYP1 A2 (e.g. fluvoxarnine) could potentially inhibH elimination of olanzapine. However, as olan· 
zapine is metabolized by multiple enzyme systems, inhibH100 ol a single enzyme may not appre-
ciably decrease olanzapine clearance. 
Potential for ZVPREXA to Affect Other Drugs: In clinical tnals with single doses of ZVPREXA, no 
inhibition of the metabolism of 1mipramine/desipram1ne (P450-CYP206), war1arin (P450-
CYP2C9), or diazepam (P450-CYP3A4) was eVIdent. ZVPREXA showed no Interaction when 
coadministered with lithium. Also, in in vitro studies With human ITliCfOSOfTleS, olanzapine showed 
little potential to inhibit cytochrornes P450-CYP1A2, -CYP2C9, -CYP2C19, -CYP206, and 
-CYP3A4 (see PHARMACOLOGY). Oianzapone IS thus unlikely to cause clinically Important 
drug-drug ~nteracbons mediated through the metaboliC routes ouU'ned above. However, the 
possibility that olanzapine may alter the metabolism of other drugs, or that other drugs may alter 
the metabolism of olanzapone, should be considered when prescribing ZVPREXA 
Pregnancy: There are no adequate and weU-controlled studies in pregnant women. Patients 
should be adviSed to notily their physiCian ~ they become pregnant or Ulland to become pregnant 
during treatment with ZVPREXA Because human expenence 1n pregnant females is irTll ed, this 
drug should be used in pregnancy only ~ the potential benefrt justifies the potential risk to the fetus. 
Labor and Delivery: Parturiticlll in rats was not affected by olanzapine. The effect of ZVPREXA 
on labor and delivery in humans is not known. 
Lactation: Oianzapine was excreted in m~k of treated rats during lactabon. ij is not known ~ olan-
zapine is excreted '" human milk. Patients should be advised not to breast feed an infant ~ they 
are taking ZVPREXA 
Geriatrics: The number of patients 65 years of age or over, With schizophrenia or related disor· 
ders, exposed to ZVPREXA. during cliniCal tnals was lirnHed (N=44). caution should thus be exer-
cised with the use o1 ZVPREXA in the -11y patient, recognmg the more trequem hepalx:, renal, 
central nervous system. and cardiovascular dyslunciJons, and more frequent use of concomitant 
medocabon Ill this population (see DOSAGE AND ADMINISTRATION). 
Children: The safety and effiCaCY of ZVPREXA in children under the age of 18 years have not 
been established. 
Renal and Hepatic Impairment Small singie-<lose cl1n1Cai pharmacology studies (see PHAR· 
MACOLOGY, Special Populations), did not reveal any major alterations in olanzapine pharmacO-
kinetics in subjects with renal or hepatic impairment. Given the limHed clinical experience with 
ZVPREXA 1n pabents with these conditions, caution sho!Ad be exercosed (see DOSAGE AND 
ADMINISTRATION). 
Use in Patients with other Concomitant Illness: Clinical expenence with olanzapine in patients 
with concomitant illness is limHed. caution is thus advised when using ZVPREXA in patients with 
diseases or conditions that could affect the metabolism or the pharmacodynamic activHy of olan· 
zapine (see PHARMACOLOGY, Pharmaookinetics, and DOSAGE AND ADMINISTRATION). 
ZVPREXA has not been evaluated in patients With a recent hiStory of myocardial infarction or 
unstable heart disease. Patients with these concibons were excluded lrom prernarketing cliniCal trials. 
As ZVPREXA demonstrated anticholinergic actJVity m vitro, caution is advised when prescribing for 
patients with symptomatic prostatic enlargement, narrow-angle glaucoma or paralytic ileus and 
related conditions. 
In clinical trials, a single case of pre-existing 1ntercranial hypertensoon exacerbated. 
ADVERSE REACTIONS 
The stated frequencies of adverse events represent the proportion of individuals who experienced, 
at least once, a treatment-emergent adverse event of the type listed. An event was considered 
treatment-emergent ~ H occurred for the first time or worsened while receiving therapy following 
baseline evaluation. tt is important to emphasize that although the events were reported during 
therapy, they were not necessarily caused by the therapy. 
The prescriber should be aware that the figures in the tables and tabulations cannot be used 
to predict the incidence of side effects in the course of usual medical practice where patient char· 
acteristics and other factors differ from those that prevailed in the clinical trials. Similal1y, the crted 
frequencies cannot be compared with figures oblained from other clinical investigations involving 
different treatments, uses, and investigators. The fiQtJres crted, however; do provide the prescnb-
'"9 physician with some basis for estimating the relative contribution of drug and nondrug factors 
to the side effect incidence in the populations studied. 
Commonly Observed Adverse Events In Placebo-Controlled Clinical Trials: The foliowlng 
treatrnerrt-emergent adverse events, derived from Table 1, commonly occurred during acute thor· 
apy with ZVPREXA• (olanzapine) \lllCidence of at least 5%, and more than double the Incidence 
observed with placebo): dizziness, constipation, All (SGPT) increased, weight gain, akalhisia, and 
postural hypotension. 
Adverse Events Associated with Dlscontlnuation: Short· Term, f'lacebo.Contro/led Qimcal 
Trials: There was no stalisticaly significant difference in rates of discontinuation of ZVPREXA or 
placebo attributed to adverse events. Overall , 5% of ZVPREXA·treated patients disconbnued 
treatment for adverse events compared with 6% of placebo-treated patients. Discontinuations due 
to All (SGPT) elevations; however, were considered to be drug related (2% for olanzapine versus 
0% for placebo) (see PRECAUTIONS). 
Short· Term, ActNI>-Controlled C/inicaJ Trials: Of the 1796 ZVPREXA·treated patients 1n cornpara-
trve clinical trl8ls with haloperidol, 98 (5%) discontinued treatment for adverse events compared 
with 66 of 810 (8%) haloperidol-treated patients 
Overal Integrated Safely Database: In a prernarketing clinocal trl81 database of 2500 ZVPREXA· 
treated patients, 14.9% (37212500) discontinued for an adverse event About hall (1831372) of 
these discontinuations were associated with the underlying psychopathology. Other adverse 
events most commonly ('lllCidence of 0.5'lo • 0.6%) reported as the reason for discontinuabon 
among olanzapine-treated patients were: All (SGPT) increased, uruntended pregnancy, creabne 
phosphokinase increased, and convulsion. 
Incidence of Adverse Events in Placebo-Controlled Clinical Trials: Table 1 enumerates the 
lllCidence, rounded to the nearest peroent of treatment-emergent adverse events that occurred 
during acute therapy (up to 6 weeks) of schizophrenia "' 1% or more of patients treated w-th 
ZVPREXA (doses ;,2.5 mg/day) where the incidence in patients treated with ZVPREXA was 
greater than the ltiCidence in placebo-treated patients. 
TABLE 1 : 
Treatment-Emergent Adverse Events 
Incidence In Placebo-Controlled Clinical Trials • Acute Phase• 
Body System/Adverse Event 
Body As a Whole 
Headache 
Pain 
Fever 
Abdominal pain 
Back pain 
Chest pain 
Neck ngidHy 
Intentional injury 
Cardiovascular System 
Postural Hypotension 
Tachycardl8 
Hypotension 
Digestive System 
Constipation 
Dry mouth 
Peroentage of Patients Reporting Event 
ZVPREXA Placebo 
(N--248) (N= 118) 
17% 15% 
10% 9% 
5% 3% 
4% 2% 
4% 3% 
4% 2% 
2% 1% 
1% 0% 
5% 2% 
4% 1% 
2% 1% 
9% 3% 
7% 4% 
Gamma glutamyl transpeptidase increased 
Increased appe!He 
2% 
2% 
1% 
1% 
Hemic and lymphatic 
leukopenia 
Metabolic and Nutritional Disorders 
SGPTIIlCreased 
Weight gamt 
Edema 
Peripheral edema 
SGOT increased 
Crealllle Phosphokinase increased 
Musculoskeletal System 
Arthralgia 
Joint Dtsorder 
Twrtchong 
Nervous System 
Somnolencet 
Agitation 
Insomnia 
Nervousness 
Hostility 
Dtzzinesst 
Anxiety 
Personality disorder 
Akalhisiat 
Hypertonia 
Speech Otsorder 
Tremor 
Amnesia 
Drug Dependence 
Euphona 
Neurosis 
Respiratory System 
Rhinitis 
Cough lllCI'eased 
Pharyngitis 
Skin and Appendages 
Fungal Dermatitis 
Vesiculobullous rash 
Special Senses 
Amblyopia 
Blepharitis 
Eye Disorder 
Corneal lesion 
Urogenital System 
Menstrual Dtsorde<l 
1% 0% 
8% 3% 
6'lo 1% 
2% 0";. 
2% 0% 
2"o 0";. 
1 •• O"o 
3"o 2"o 
2"o 1'lo 
2"o 1'lo 
26% 15% 
23% 17% 
20% 19'lo 
16% 14% 
15% 14% 
11% 4% 
9% 8% 
8% 4% 
5% 1% 
4% 3% 
4% 10'0 
4 ... 3"o 
2% ()% 
2"o ()% 
2"o O"o 
1'lo O"o 
10% 6% 
5% 3% 
5% 3% 
2% 0% 
2% 1% 
5% 4% 
2% 1% 
2% 1% 
1% 0% 
2% 0% 
"The foflowtng events had an incidence equal to or less than placebo: abnormal dreams, acct· 
dental intury, anorexia, apathy, asthenia, cogwheel rigidity, confusion, conjunctivitis, depression, 
diantlea, dysrnenontoeai. dyspepsia, ecchymosis, emotional labiiHy, hallucinations, hyperkine-
sia, hypertension, hypokinesia, libido increased, myalgia, nausea, paranoid reaction, paresthe-
sia, pruritus, rash, schizophrenic reaction, sweating, thinking abnormal, tooth caries, vaginitis;, 
vomiting. 
tStatistlcatty signif1C811tly more frequent in patients treated with ZVPREXA than in patients treated 
with placebo. 
t:Denorninator used was for females only (N=41 ZVPREXA; N=23 Placebo). 
Incidence of Weight Changes In Placebo-Controlled Clinical Trials: During acule therapy (up 
to 6 weeks) in controlled clinical trials comparing lYPREXA with placebo in the treatment of schiz-
ophrenia. the percentages of patients with weight gain ~ 7% of base~ne body weight at any time 
were 29% for lYPREXA and 3% for placebo, which was a statistically significant difference. The 
average weight g<Pl during acule therapy in patients treated with lYPREXA was 2.8 kg. However, 
a categorization of patients at baseline on the basis of body mass index (BMI) revealed a signifi-
cantly greater effect in patients with low BMI compared to normal or overweight patients. In long-
term extension trials weight gain tended to level off after 6-8 months of treatment, with an average 
ga1n of 5.4 kg (see PRECAUTIONS). 
Incidence of Vital Sign Changes In Placebo-Controlled Clinical Trials: In Placebo-Controlled 
clinical trials , orthostatic hypotension (greater than 30 mm decrease in systolic blood pressure) 
occurred with an incidence of 5% in olanzapine-treated patients compared to 2% in placebo-treat-
ed patients (vital sign measurements collected only after 3-7 days of lYPREXA treatment). 
Olanzapine was assoaated with a mean baseline to endpoint increase in heart rate of 2.4 beats 
per minute compared to no change among placebo-treated patients (see PRECAUTIONS). 
Incidence of Laboratory Changes In Placebo-Controlled Clinical Trials: Olanzapone is assoa-
ated with asymptomatic InCreases in SGPT, SGOT, and GGT (see PRECAUTIONS). Olanzapine is 
also associated with generally mild increases in serum prolactin, which usually decreases with 
continued drug treatment. Olanzapine is also associated with asymptomatic elevations ol 
eosinophils and uric acid (see PRECAUTIONS). and with decreases in serum bicarbonate. 
Incidence of ECG Changes In Placebo-Controlled Clinical Trials: Between-group comparisons 
for pooled placebo-controlled trials revealed no statisticatly significant olanzapinelplacebo differ-
ences 1n the proportions of patients experiencing potentially important changes in EGG parame-
ters, including OT, OTc. and PR 111tervals. 
Dose-Dependent Adverse Events In Fixed-Dose Clin ical Trials: Dose-relatedness of adverse 
events was assessed us1ng data from a clinical trial with a fixed dosage range. Table 2 enumer-
ates the treatmeni-Mlergenl adverse events 1n which there was a statistically significantly 
incre8Sing dose response in this clinical trial. 
TABLE 2 : 
Dose-Dependent Adverse Events In a Fixed Dosage Range, 
Placebo-Controlled Clinical Trlat• 
Body System/ 
Adverse Event 
Digestive System 
Constipation 
Nervous System 
Abnormal dreams 
Dizziness 
Somnolence 
Respiratory System 
Pharyngitis 
Placebo 
(N--68) 
0% 
0% 
2.9% 
16.2% 
1.5% 
Percentage of Patients Reporting Event 
lYPREXA lYPREXA 
5 % 2.5 mg/day 1 0 ± 2.5 mg/day 
(N=65) (N=64) 
6.2% 9.4% 
0% 1.6% 
7.7% 9.4% 
20.0% 29.7% 
3.1% 1.6% 
lYPREXA 
15 ± 2.5 mg/day 
(N=69) 
14.5% 
4.3% 
17.4% 
39.1% 
10.1% 
'Fungal dermatitis was also reported with a statistically sigrificantly increasing dose response, 
but is not included as a drug cause was remote. 
Incidence of Treatment-Emergent Extrapyramidal Symptoms in Placebo-Controlled Trials: 
Table 3 enumerates the percentage of patients with lreatmenl-<!1118rgent extrapyramidal symptoms 
as assessed by categorical analyses of formal rating scales during acute therapy in a controlled 
clinical trial comparing ofanzapine at 3 fiXed dosage ranges with placebo in the treatment of 
schizophrenia. 
TABLE 3 : 
Treatment-Emergent Extrapyramidal Symptoms Assessed By Rating Scales 
Incidence In A Axed Dosage Range, Placebo-Controlled Clinical Trial -Acute Phase• 
Percentage of Patients 
lYPREXA lYPREXA lYPREXA 
Placebo 5 ± 2.5 mglday 10 ± 2.5 mglday 15 ± 2.5 mglday 
Partonsonism' 15% 14% 12% 14% 
Akathisia2 23% 16% 19% 27% 
'No statistically sign~icanl differences. 
'Percentage of patients with a Simpson-Angus Scale total score >3. 
2Percentage of patients with a Sames Akathisia Scale global score ~-
Table 4 enumerates the percentage of patients with treatmenl-<!1118rgent extrapyramidal symptoms 
as assessed by spontaneously reported adverse events during acule therapy in the same con-
trolled clmical trial comparing olanzapine at 3 fixed dosage ranges with placebo in the treatment of 
schizophrenia. 
TABLE 4 : 
Treatment-Emergent Extrapyramidal Symptoms Assessed by Adverse Events 
Incidence In a Axed Dosage Range, Placebo-Controlled Clinical Trial -Acute Phase 
Percentage of Patients Reporting Event 
Extrapyramidal Symptoms Placebo 
(N=68) 
Dystonic eventst 1% 
Partonsonism evenlsl 10% 
Akath1s13 events§ 1% 
Dyskinetic eventsll 4% 
Residual eventsl 1% 
Any extrapyramidal event 16% 
lYPREXA lYPREXA lYPREXA 
5 ± 2.5 mglday 10 ± 2.5 mglday 15 ± 2.5 mg/day 
(N=65) (N=64) (N=69) 
3% 2% 3% 
8% 14% 20% 
5"'- 11%' tO%• 
0% 2% 1% 
2% 5% 1% 
15% 25% J2%• 
• Statistically signifiCantly different from placebo. 
t Patients with the following COST ART terms were counted in this category: dystonia, generalized 
spasm, neck rigidity. oculogyric crisis, opisthotonos, torticollis. 
i Patients with the following COSTART terms were counted in this category: akinesia. cogwheel 
ngldity. extrapyramidal syndrome, hypertonia, hypokinesia, masked facies, tremor. 
§ Patients with the following COST ART terms were counted in this category: akathisia, hypert<ines&a 
II Patients with the following COSTART terms were counted in this category: buccoglossal syn-
drome. ctloreoathetosis, dyskinesia, tardive dyskinesia. 
I Patients with the following COST ART terms were counted in this category: movement disorder, 
myoclonus. lwi1ching. 
SYMPTOMS AND TREATMENT OF OVERDOSAGE 
Experience with lYPREXA• (ofanzapine) in overdosage is im~ed. In clinical trials, accidental or 
Intentional acute overdosage of lYPREXA was identified in 67 patients. In the patient taking the 
largest identified amoun~ 300 mg. the only symptoms reported were drowsiness and slurred 
speech. In the lim~ed number of patients who were evaluated in hospitals, including the patient 
taking 300 mg, there were no observations indicating an adverse change in laboratory analyles or 
EGG. Vllal signs were usually within normal limits following overdoses. 
Based on animal data, the predicted symptoms would reflect an exaggeration of the drug's 
known pharmacological actions. Symptoms may include somnolence. mydriasis, blurred vision. 
respiratory depression. hypotension, and possible extrapyramidal disturbances (see also ANIMAL 
TOXICOLOGY). 
There is no specffic antidote to lYPREXA; therefore, appropriate supportive measures should 
be initiated. The possibility of multiple drug involvement should be considered. 
In case of acule overdosage, establish and maintain an airway and ensure adequate oxy-
genation and ventilation. The use of activated charcoal for overdose should be considered 
because the concomitant administration of activated charcoal was shown to reduce the oral 
bioavailability of lYPREXA by 50% to 60%. Gastric lavage (alter intubation, ~ patient is uncon-
scious) may also be considered. 
Hypotension and circulatory collapse should be treated with appropriate measures such as 
JOtravenous fluids and/or sympathomimetic agents such as norepinephrine (do not use epineph-
rine. dopamine or other sympathomimetic agents with beta-agonist activity since beta stimulation 
may worsen hypotension in the setting of alpha blocl<ade induced by lYPREXA). Cardiovascular 
monrtonng should commence immediately and should include continuous electrocardiographic 
monrtoring to detect possible arrhythmias. 
Close medical supervision and monitoring should conbnue until the patient recovers. 
DOSAGE AND ADMINISTRATION 
(see also CLINICAL PHARMACOLOGY) 
Adults: lYPREXA" (ofanzapine) should be administered on a once-a-day schedule without regard 
to meals, generally beginning with 5 to 10 mg. with a target dose of 10 mglday within several 
days. Furiher dosage adjustments, ~ indicated, should generally occur at intervals of not less than 
1 week. since steady state for lYPREXA would not be achieved for approximately 1 week n the 
typical patient When dosage adjustments are necessary, dose increments/ decrements ol 5 mg 
00 are recommended. An increase to a dose greater than target dose of 10 mglday ~.e ., to a dose 
of 15 mglday or greater) is normally recommended only after clinical assessment 
In clinical trials a dose range of 5-20 mglday was studied (see CLINICAL TRIALS). The safety 
and etfJCaC)I of doses above 20 mglday have not been evaluated. 
The elderly or debilitated patient: In clinical trials, 44 patients with schizophrenia or related dis-
orders, 65 years of age or over. were treated with lYPREXA (5-20 mg daily) (see PRECAUTIONS; 
see also PHARMACOLOGY, Special Populations). Given the ~m~ed experience with lYPREXA 
in the -rly. and the higher incidence of concomitant illness and concomitant medication in this 
population, lYPREXA should be used with caution. 
The recommended starling dose IS 5 mg in patients who are -11y. debilitated, who have a 
predisposition to hypotensive reactions, who otherwise exhibit a combination of faclors that may 
resu~ 1n slower metabolism of lYPREXA (e.g., nonsmoking female patients), or who may be 
pharmacodynamically more sensitive to lYPREXA. When indicated, dose escalation should be 
performed with caution in these patients. 
Patients with Hepatic and/or Renal Impairment: As clinical experience is lacking in these 
patients, the lower initial starting dose and slower titration to inibal target dose should be consid-
ered. Furiher dose escalation, when indicated. should be conservative (see PRECAUTIONS; see 
also PHARMACOLOGY, Special Populations). 
Maintenance Therapy: It is recommended, that responding patients be continued on lYPREXA 
at the lowest dose needed to mainllm remission. Patients should be reassessed penodically to 
determme the need for ma1ntenance treatment While there is no body of evidence available to 
answer the question of how long the patient should be treated with lYPREXA, the effectiveness of 
maintenance treatment is wen established for many other antipsychotic drugs. 
PHARMACEUTICAL INFORMATION 
DRUG SUBSTANCE : 
Trade Name: lYPREXA" 
Proper Name: Olanzapine 
Chemical Name: 2-Methyl-4-(4-methyl-1-piperazinyf)-1 OH-thieno[2.3-b) (1 ,5) 
benzodiazepine 
Structural Formula: 
Molecular Formula: C,,.H..N,S 
Molecular Weight: 312.44 
Description : Olanzap!ne is an antipsychotic agent of the thienobenzodiazeptne 
class. It is a yellow crystal1ine solid, which is soluble in 
n-Propanof and practically insoluble in water. 
pK.: 5.00 and 7.40 in DimethyHormamide/Water (60:40. v/v) 
Melting Point: 195 ± 2"C 
COMPOSITION : 
Each lYPREXA (olanzapine) tablet contains the equivalent activity of 5 mg (16 ~tmof), 7.5 mg 
(241!mof). or 10 mg (32~tmof) of olanzapine. Inactive ingredients include camauba wax, color mix-
ture white (hydroxypropyl methytcel1ulose, titanium dioxide, polyethylene glycol, and polysortlate 
80), crospovidone, FD&C Blue No. 2 Aluminium Lake, hydroxypropyl cellulose, hydroxypropyt 
methylcellulose, laclose, magnesium stearate. and microcrystaHine cellulose. 
STABILITY AND STORAGE RECOMMENDATIONS : 
Store tablets at 20· ·25•c . Protect from light and moJSture. 
AVAILABILITY OF DOSAGE FORMS : 
All tablets are wh~e. round, film-coated, and imprinted in blue ink with "LILLY" and the tablet iden-
bflcabon code. Each strength is available in amber HOPE bollles of 60 tablets. 
TABLET STRENGTH 
5mg 7.5mg 10mg 
Tablet No. 
Imprint 
4115 
LILLY 
4115 
4116 
LILLY 
4116 
4117 
LILLY 
4117 
Product Monograph available on request. October 15, 1996 . 
G:J~ 
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Scarborough, Ontario 
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Feature Sect i o n 
STRESS REACTIONS OF THE DISTAL 
RADIAL EPIPHYSEAL 
PLATES IN YOUNG GYMNASTS 
ABSTRACT 
T his paper is a report on stress injuries to the distal radial epiphyses of young gymnasts. These injuries are common in young gymnasts as a result of the 
repetitive, upper-limb weight-bearing characteristic of the 
sport. The topic is introduced with reference to the case of 
an eight-year-old gymna t with damage to the dis tal 
epiphyseal plate of her left radius. Pathogenesis, 
diagnosis, treatment, epidemiology, etiology, prognosis, 
implications, and prevention of stress injuries to the distal 
radial epiphyses are discussed. 
INTRODUCTION 
As a result of upper-limb weight bearing, the wrists 
of young gymnasts are exposed to unusually large 
amount of stress. The stress from repetitive, high-impact 
loading may damage their distal radial epiphyseal plates. 
This damage may occur as a stress fracture, or as a stress 
reaction characterized by irregularity of the metaphyseal 
margin, widening, cystic changes, and sclerosis of the 
epiphyseal plateY Damage to the epiphysis warrants 
concern as i t may lead to premature closure of the 
epiphyseal plate and disrupted growth. 'u.• It is important 
tha t gymnastics coaches, parents, and physicians 
understand the risks, implications, and symptoms of 
these stress injuries, in order that any such injury be 
recognized and treated early. The goal of this paper is to 
provide information on all aspects of stress injuries to the 
distal radial epiphysis. 
CASE STUDY 
In February 1995, an eight year-old eli te, female 
gymnast presented with left wrist pain. In January 1994, 
the gymnast fell off the uneven parallel bars and landed 
on an outstretched arm, forcing her wrist into 
hyperextension. Plain film radiographs showed a Salter 
Type II fracture of the distal radius. The fracture was 
treated by means of cast immobilization for three weeks. 
Repeat x-rays taken at the end of the month showed a 
small amount of periosteal bone forma tion over the 
dorsal surface of the radius, and otherwise little change. 
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The injury occurred during the athlete's fourth year 
of participation in gymnastics. She was also involved in 
dance and karate . At the time of the injury, she was 
training at gymnastics for approximately 18 hours per 
week. Following the removal of her cast, the gymnast did 
physiotherapy and gradually, over a period of one 
month, returned to her full training schedule. In January 
of 1995, while training 18-20 hours per week, the gymnast 
w as experiencing wrist pain during workouts . She 
noticed a bump on the dorsum of her wrist. Repeat x-rays 
showed irregularity of the epiphysis and slight dorsal 
tilting of the distal radius. The radiograph also showed 
slight attenuation of the ulnar aspect of the epiphysis, 
suggesting disturbed growth. At this point, the gymnast 
presented at the Allan McGavin Sports Medicine Centre. 
The physical exam showed the following . The left 
elbow had full, pain-free range of motion. The left wrist 
had full range of motion, with mild dorsal-radial 
swelling. The gymnast had full power, and no pain on 
forced flexion or extension. She did not experience pain 
during normal, daily activities. There was full 
neurovascular function. The physician reviewed the 
results of the radiographs and noted the indications of 
damage to the growth plate. 
Treatment involved reducing training to 10 hours per 
week and starting a physiotherapy program focusing on 
wrist strength and flexibility. The gymnast began to use a 
rigid wrist brace during activity, and ice to reduce pain 
and swelling post-activity. It was recommended that if 
pain continued despite these measures, she should 
terminate her participation in gymnastics and place more 
emphasis on dance. It was also recommended that if her 
condition improved and she was able to increase her 
training pain-free, she should train less than 12-14 hours 
per week. Upon re-examination in September of 1995, she 
reported that training for three consecutive days 
aggravated her wrist. She could, however, train for 3 
hours a day on alternate days (a total of 12 hours per 
week) without any discomfort. 
DISCUSSION 
PATHOGENESIS 
The epiphyseal plate is a cartilaginous disk between 
the epiphysis and metaphysis. Here cartilage cells 
proliferate and calcify during endochondral ossification. 
The cartilage of the epiphy eal plate is one of the weakest 
skeletal structures in the young athlete. It is estimated to 
be 2 to 5 times more likely to sustain injury than the joint 
capsule and other ligaments. 5 Consequently, it is 
susceptible to both acute and chronic injuries. When 
fractured, the epiphyseal plate tends to separate between 
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the calcified and uncalcified cartilage at the metaphyseal 
junction. This area is avascular, and consequently, there 
tends to be a limited amount of swelling a ociated w ith 
its fracture.6 When injured, the epiphy eal plate tends to 
widen due to continued production of cartilage cells 
despite disturbed bone formation.6 Other stress-related 
changes include cystic changes (usually on the 
metaphy eal aspect of plate), clerosis, irregularity of the 
metaphyseal margin, widening of the epiphysis, and a 
haz y appearance of the ep iphyseal plate on 
radiographs.1.2 
DIFFERENTIAL DIAGNOSIS 
In diagnosing chronic wrist pain in a young gymnast 
one must consider a number of possible injuries. Some of 
the e include stress reaction or stress fracture of the distal 
radial epiphysis, ligament injury, chondromalacia, 
tendonitis, degenerative joint disease, stres fracture of the 
radius, ulna, or a carpal bone, tumour, cartilage damage, 
and damage to the triangular fibrocartilage complex. The 
phy ical exam may enable the physician to diagnos the 
presence or absence of tendonitis; however, fur ther 
diagnoses will require investigative techniques. The plain 
film radiograph may not how stress fractures, but it will 
show signs of stress reactions in the epiphyseal plate. It has 
been suggested that information from a technetium-99 
bone scan is of little use in the diagnosis of epiphy eal 
plate injuries: A normal epiphyseal plate ha high uptake, 
and injured epiphyses have been found to show uptake 
which is normal for the patient' ageY However, the bone 
scan ma y be useful in eliminating other possible 
diagnoses . Mandelbaum et al. suggest that MRI is 
particularly useful in the diagnosi of gymnastic w rist 
injuries as it effectively differentiates between and shows 
damage to various types of tructures and tissues.8 
A diagnosis of a stres fracture or stres reaction of the 
distal radial epiphyseal plate can be made based on the 
following : exposure to a s tress mechanism, such as 
repetitive weight-bearing, localized pain and tenderne 
over the distal radial epiphy i , pain in response to forced 
dorsiflexion and ometimes with radial or ulnar deviation, 
minimal swelling, and radiographs showing a fracture or 
other stress related changes as described previously.2 The 
gymnast in this case study had a history, physical findings, 
and radiographs con i tent w ith disruption of the 
epiphyseal plate as a re ult of an acute fracture of the 
epiphysis and continued expo ure to stress. 
TREATMENT 
Treatment of injuries to the distal radial epiphyseal 
plate hould begin con erva tively, including rest from 
weight-bearing, non-steroidal anti-inflammatory drugs, 
physical therapy using multiple modalities, and ice. Some 
injuries may require temporary cessation of gymna tics 
and immobilization.8 A a guideline, weight-bear ing 
should be avoided until the wrist is no longer tender to 
touch and there is no pain with forced range of motion, 
especially in dorsiflexion.2 The athlete should undertake a 
strengthening program for upper body and wrists, 
keeping activity within a pain-free limit. Return to activity 
should be gradual and progressive, allowing time for the 
body to adapt to stress.2 To protect the wrist from further 
damage, the wrist can be taped, or the gymnast can be 
fitted with a rigid wrist brace. These methods will help the 
gymnast to avoid excessive hyperextension of the wrist. 
EPIDEMIOLOGY 
A tudy of 100 provincial and national level gymnasts 
showed a high injury rate amongst the participants, with 
155 acute and 124 chronic injuries sustained over 40 
months.9 In this study, 4.5% (7) of the acute injuries were 
fracture of the forearm or wrist, and 1.6% (2) of the 
chronic injuries were distal radial stress fractures. Despite 
having a high injury rate, the sport of gymnastics is very 
popular, with an estimated 600,000 participants in the 
United States alone.2 
Recently, there has been a trend toward early 
participation in gymnastics which has sparked special 
concems.2 Prepubescent athletes have open growth plates 
which are susceptible to damage. This damage may have 
significant long-term effects. 
Damage to the distal rad ial epiphysi ha been 
identified as a common problem for gymnasts. Stress 
changes of the distal radial epiphyseal plates were obvious 
in 10% of gymnasts at the World Champion hip 
Gymnastics Competition in Rotterdam in 1987/ and in 11 
of 21 (42%) high performance gymnasts studied by Roy.2 
Epiphyseal plate fractures are most often reported in 
competitive gymnasts, but al o occur in individuals at 
lower skilllevels.10 
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Factor related to the occurrence of injuries to the 
di tal radial epiphysis in gymnasts include the nature of 
the skills and the sport, the amount of exposure, and the 
equipment. 
Many gymnastic kills involve high-impact loading 
on the upper extremities. For example, the compressive 
ground reaction forces experienced during a back 
handspring (a fundamental and frequently repeated skill) 
may be up to 2 .4 times bod y weight. ' Repeated 
compre sive forces have been indicated as the primary 
cau e of chronic wrist injuries in gymnasts. 7-" Other 
contributing factors include a combination of 
hyperextension and ulnar deviation during vaulting and 
tumbling (especially during skill in olving rotation or 
twi ting), and the torques applied through the wrist 
during balance beam and pommel hor e activitie . In 
the e activitie the hands are fixed while the rest of the 
body rotates around them.2•10 Many gymnastics skills 
involve flight. The nature of these flight moves favour the 
prepubescent gymnast. 4 This has resulted in early 
participation, with young gymnasts training up to thirty 
hours per week and exposing their growing bones to high 
levels of repetitive physical loading.24 Consequently 
there is a high risk of growth plate injuries in young 
gymnasts. 
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Gymnastics i by nature a repetitive sport. Gymnasts 
repeat skills and routines time and time again, striving for 
perfectionY0 A a re ult, their bodies experience repetitive 
rnicrotrauma. This trauma may result in stress fractures. 
Fractures of the distal radial epiphyses of gymna t are 
commonly stress fractures cau ed by overuse/ ·" but can 
also re ult from acute injury, such as in this case where 
the gymnast fell onto an out tretched arm. An injury 
whose onset is acute may be aggravated and kept from 
healing by continued exposure to stress. Some exerci e 
has been found to be beneficial, promoting bone growth 
and hypertrophy, but the inflammation, disruption of 
normal growth, and degenerative changes in the bone of 
competitive gymnasts show that the e athletes' bodies are 
being stressed beyond their tolerance level. 5 The 
epiphy eal plate is a weak area of growing bone and is 
consequently a common site of injurie .5 
Injuries to the distal radial epiphyses of gymnasts 
were found to be related to exposure. Literature citing 
wrist pain in gymnasts describe pain occurring, for the 
most part, in gymnasts training between 15 and 30 hours 
per week_I.2.3.4.s The risk of injury was found to be directly 
proportional to the skill level." This was suggested to be a 
result of increased training hours and the execution of 
riskier and more difficult kills at higher levels of 
training. II 
Equipment was al o indicated as a contributing factor 
to wrist injurie . It was sugge ted that the use of soft mat 
may exaggerate dor iflexion.2 Also, the use of dowel grips 
on bars transfers forces from the hands to the wrists. 7· ' 0 
Floor exercise, beam, and pommel horse are most often 
indicated as causing pain, likely as a result of the torques 
and forces applied through the wrists during these 
activitie .2.• 
PROGNOSIS, IMPLICATIONS, A D PREVENTION 
Wrist pain results in loss of training time and 
consequently decreased performance.8 More eriou ly, 
injurie to the distal radial epiphysis may result in 
premature closure of the epiphyseal plate and / or 
di ruption of growth.'.2..34 With ongoing, normal growth 
of the ulna, this may lead to po itive ulnar variance. In 
current literature there is admitted uncertainty 
concerning whether or not the exposure of gymnasts ' 
wrists to repetitive microtrauma will result in permanent 
damage, and at what level of training the stress becomes 
too much for the bones to handle. However, studies of 
world-class and collegiate gymnasts show that both 
adolescent and adult gymnast have highly significant 
levels of positive ulnar variance when compared to non-
athlete control groups. '-" This uggests that participation 
in competitive gymnastic at the collegiate and 
international level does disrupt the growth of the radius, 
and that thi damage is long-term. Furthermore, positive 
ulnar variance has been implicated as a predispo ing 
factor in damage to the triangular fibrocartilage, ulnar 
impaction yndrome, cystic changes in the triquetrum, 
chondromalacia, degenerative arthritis of the ulnar 
compartment, and osteomalacia of the ulnar carpals.'.2.s 
We can therefore conclude that damage to the distal 
radial epiphysis in gymnasts is a serious injury with 
potentially life-long consequences. 
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On a more positive note, it ha been found that if 
the growth plate injury is diagnosed early and the 
athlete responds quickly with conservative treatment, 
the prognosis for recovery is very good.2 
Stress reaction to the distal radial epiphys s of 
gymnasts are a small part of a much larger issue. They 
reflect phy ical tres . Young gymna t al o experience 
emotional stress associated with learning high-risk 
moves, travelling, and competing . They are under 
inten e pressure to win brought upon by their coaches, 
their parents, and society.12 We mu t ask ourselves if 
this is right. Should children be exposed to this 
magnitude of physical and emotional stress? How much 
competition and training is too much? Should children 
participate in a sport at a level which may result in life-
long damage? Would these children be better off 
participating in a variety of sports?12 What can we do to 
help? These are difficult questions to an wer. Society 
put a great deal of emphasis on winning, and winning 
major athletic event i associated with much pre tige. 
Society's "win at all co ts" attitude would be hard to 
change. 12 
If we are unable to change the outcome-oriented 
approach to athletics, perhaps we can at least control 
the process of training and reduce the number of 
injuries. This prevention will begin with the education 
of coaches, parents, and gymnasts regarding the risks 
associated with gymnastics and how they ma y be 
avoided. Proper conditioning programs which develop 
strength and flexibility should be implemented a t all 
levels of training. 9 Increases in training should be 
gradual and cyclic in nature, allowing the body time to 
adapt to new stresses. Gymnasts with open growth 
plates in their wrists should not use dowel grips .7 
During practice, they should alternate between 
swinging and weight-bearing even ts Y They should 
learn and practice correct falling and landing 
techniques.9 The presence of trained, knowledgeable, 
experienced spotters and the proper use of afe ty 
equipment (such as mats and spotting belts) are highly 
recommended. 11 It is also important that exposur is 
limited to less than 15 hour per week, and that 
gymnasts do not participate when in painY Finally, 
rapid diagnosis and treatment of both chronic and acute 
injuries is essential.5 
CONCLUSIO 
Inflammation, disruption of normal processes of 
growth, and degenerative changes in bone reflect that 
the bodies of competitive gymnasts are being physically 
stressed beyond their tolerance level. Damage to the 
epiphyseal plate i common in gymnasts, and while 
early diagno is and conservative treatment of the injury 
has a good progno is for recovery, if left untreated the 
injury may have erious, life-long effect . Steps mu t be 
taken to prevent epiphyseal plate injuries in young 
athletes. These steps include education of coaches, 
parents, and gymnast, a safe training environment, and 
limiting exposure to weight-bearing by the upper 
extremities. 
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The Neuropsychology 
Syndrome 
of Turner's 
I n 1938, a syndrome was identified in which there was sexual immaturity, small stature, and skeletal abnormalities due to a full or partial deletion of the X 
chromosome in somatic cells'. One of the most widely 
studied aspects of thi disorder is its associated 
neurocognitional and behavioural differences. Many 
competing theories have been propo ed to account for the 
specific neuroanatomical areas in which there are 
anomalies, as well as the bases for the production of such 
impairments in brain, behaviour, and ability. 
EUROCOGNITIONAL DIFFERENCES 
In developmental neuropsychological deficits, uch 
as those produced by Turner's syndrome, there is no 
contrast between a previous state and the pre ent one. 
Only the final result of the deficit and the individual's 
attempt to compensate are exhibited. Thus, psychology 
ha been slow to accept and identify such ca es 2 • 
Turner' patients most predominantly displa y five 
major cognitional differences, as compared to normal 
subjects. 
by Tulin Cit, Meds 2000 
PERFORMANCE VS. VERBAL IQS 
The Wechsler IQ scale are used as a measure of basic 
cognitive function. These tests have a distinct advantage: 
they provide eparate score for verbal and performance 
subtests, as well as overall IQ. 3 Previous 
neuropsychological studies of patients diagnosed 
clinically and cytogenetically as Turner's syndrome have 
indicated that Wechsler performance IQs in the disorder 
ranged significantly lower than the verbal IQs (Figure 1 
illustrates the IQ results found in Temple and Carney's 
tudy '). Other authors 2 ha e also noted that on the 
Wechsler Performance IQ te t low scores were over 
represented for Turner's girls. 
VISUOSP A TIAL ABILITY 
Researchers have found that instead of an overall 
mental deficiency, which wa often ascribed to Turner 's 
patients , there are specific non verbal cognitive 
impairment that include difficulty with visuospatial 
tasks such as perception of left and right a nd 
visuomotor drawing• . In normal children, a ex 
Figure 1: Mean Verbal , Performance and Full-Scale IQ Scores 
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difference is evident between males and females on 
both Object Assembly and Block Design subtests of the 
Wechsler Intelligence Test for Children (Revised), with 
girls performing more poorly than boys '. Results of a 
study by Temple and Carney ' suppor ted previous 
findings that in Turner's patients, this sex difference 
was exaggerated, producing an even greater deficiency 
for Turner's girls in those Wechsler subtests . 
The basic impairment may be associated with 
mental processing and sequencing of rotational shape 
transformations in the spatial dimensions of up down, 
left right and back front5• 6 • In daily activities, this 
deficit in rotational transformation is manifested as a 
handicap in map reading , drawing floor plans , 
following travel directions, and recognizing facial 
expression changes6 • Ironically, the rotational 
transformation disability is not a handicap in learning 
to read, and in fact it may be an advantage. Owing to 
this impairment, the shapes of letters and words 
maintain their meaning by remaining sta tic and 
unrotated . Such a cognitive ability specific to Turner's 
girls could contribute to an easier process of learning 
to read and thus could be an explanation for their high 
verbal abilities. 
More generally, individuals with Turner 's 
syndrome have performed worse on a variety of 
visuospatial processing tasks such as spatial reasoning 
and extrapersonal space 7, visual memory, mazes, 
visual sequencing and discrimination8, and design 
copying•. 
MEMORY 
In one study5, Turner 's subjects underwent 
neuropsychological testing in order to determine the 
hormonal constraints which govern non verbal 
memory processes. Results showed that subjects had 
memory deficits for non verbal materials within three 
perceptual areas: visual, auditory, and tactile . This 
type of memory impairment was attributed to an 
alteration in the processing of the material to be 
remembered. Waber• also found deficiencies in 
Turner's patients for the houses and faces components 
of the Face Recognition test, illustrating that Turner's 
patients have a visual memory deficit for non verbal 
materials. 
NUMERICAL ABILITY 
The Wechsler test has also shown that a relative 
difficulty with numbers, a form of dyscalculia, is 
associated with the syndrome. Results of Waber 's• 
study also supported this finding by showing that 
Turner's syndrome subjects scored significantly lower 
on overall mathematics achie ement, numerical 
reasoning, and geometry and symbols. Analysis of 
math processing mechanisms revealed that areas 
which involved mathematical concepts seemed to be 
compromised to a greater degree than computational 
areas. Multiplication was the least affected. The 
previous deficiency in rotational transformation also 
serves as a handicap in certain mathematical tasks, 
especially geometry. 
Feature Sect on 
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T H E IMPACT O F M O SAIC ISM O N CO G ITIVE 
D EFICIE CIES 
Mosaicism in Turner ' yndrome genotype i a 
condition characterized by a combin.ation of normal and 
abnormal cell lines. It is suggested that various a pects 
of the syndrome's cognitive effects may be less s vere 
among those with mosaicism '. Thus, the behavioural 
phenotype of Turner's patients with mosaic genotype is 
less deviant from the normal pattern than is that of pure 
45XO. Mo aicism is found to cause a less dramatic 
expression of the syndrome, as occurs in other genetic 
disorder . 
U DERL YING CAUSES OF NEUROCOGNITIO AL 
AND A ATO M ICAL DIFFERENCES 
Many studies have implicated various 
neuroanatomical areas in which impairments might 
result in the pattern of the cognitive deficits described 
abo e. However, the underlying mechani m(s) through 
which these impairments are produced are still vague. 
Three main theories as to the cause of brain, 
behavioural, and cognitive differences for those afflicted 
with Turner' yndrome are propo ed. 
G E ETIC 
Individuals with Turner's syndrome, who lack the 
genetic material provided by the X chromosome, are 
thought to be predisposed to certain cerebral anomalies9• 
These defects are predominantly localized to the most 
recently de eloped cortical regions. The disturbances 
in function are evident in those cognitive processe 
associated with the e brain areas, specifically the 
posterior right hemi phere. 
MATURATIO AL D ELAY 
Waber• propo ed the idea of maturational delay as 
a cause of neurop ychological difference in Turner 's 
girls. This hypothesi stems from the notion that this 
syndrome i a developmental disorder. Thus, it is of 
interest to note that the performance of these 
individuals qualitatively resemble that of the pre 
pubertal child . The e patient exhibit an immature 
pattern of performance, and this immaturity translates 
into other areas of cognitive and perceptual 
functioning as well. For example, the inability to 
perceive right and left on another person could reflect 
a maturational delay, since these processes trikingly 
improve between the ages o f six and ten in normal 
subjects. 
Empirically, there is also electrophysiological 
evidence to upport thi hypothe is. It has been noted ' 
that adult Turner 's syndrome patients display an 
averaged e oked response which is most similar to 
that of female children between the ages of six and 
nine. Thi finding has been most readily attributed to 
the postulated immaturity of the cerebral cortex. 
HORM O NAL 
Evidence from laboratory studies indicate that 
gonadal hormones play a crucial role in the normal 
cerebral matura tion of many mammalian specie 2• In 
applying this hypothesis to human studies, and more 
specifically to Turner 's patient tudies, it is difficult 
to separate the effects of the genetic anomalies cited 
previously from the effects of hormonal absence. 
However, sex hormones, which are missing as a 
result of o arian dysgenesis, may serve as key factors 2• 
A lack of hormone at a critical period of embryonic 
development could exert an influence on the evolving 
central nervou y terns. Money2 proposed that this 
process of hormonal influence is involved in the neural 
mechanisms of territoriality and territorial defence, 
which are sex differentiated, being stronger in the 
male. A connection between these behaviours and 
spatial ability is then made by postulating the existence 
of a hormonal mechanism within the period of fetal 
development which might consequently affect space 
perception as it relate to territorial behaviour. 
These three theorie , proposed to attribute causality 
of neurocognitional deficits and neuroanatomical 
anomalie to specific mechanisms, are not complete by 
any means. Each fails to take into account certain 
aspects of the condition. one mention the effect of 
environmental influence , most likely because Turner's 
syndrome is looked at in such a biological and genetic 
manner. Rove di cusses the implications of certain 
environmental factor , citing a 1987 study by Bender, 
Linden, and Robinson which showed that children with 
sex chromosome abnormalities (including Turner's) 
from poorly functioning families were more impaired in 
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their intellectual and psychosocial development than 
were those from better functioning families. Thus, when 
comparing level of function in Turner' patients, it i 
important to consider the specific environmental and 
familial background of each girl. 
Each of these theories -genetic, maturational delay, 
and hormonal - offers only part of an explanation of the 
causal chain. Chromosomal abnormalities can alter 
brain development because they can lead to deviations 
from normal hormonal levels and sensitivity. 
Alterations in hormone exposure, in turn, can lead to 
differential brain development which manifests itself as 
cognitive and behavioural impairments. In this context, 
environmental influences al o ac t to determine the 
ex tent of hormonal effects, and thus the severity of 
deficiencies. 
Turner's syndrome, like so many o ther biological 
and genetic disorders which reveal neurocognitional 
alterations, is the result of a dynamic relationship 
between genetics, endocrinology, and environment. 
Each factor serves to magnify or diminish th e 
consequences of this mysterious disorder. Through it 
tudy, we may learn to aid those afflicted wi th it, and to 
develop a better understanding of the remarkable 
functions of the mind and body. 
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Second-Line 
Otitis 
There has been a lot of debate regarding the ideal treatment of acute otitis media (AOM) in children. Most parties have agreed that amoxicillin is 
probably the best first-line therapy. However, until 
recently there has been little consensus as to which 
treatment is ideal when first-line therapy is not 
effective. The efficacy of an antimicrobial is asses ed by 
culturing middle ear fluid before and after 
administration of a drug. Based on the results of 
several studies, the Ontario Antilnfective Review Panel 
provided recommendations for management of AOM 
(Appendix 1). Recommended first-line therapy is 
amoxicillin or pivampicillin. Second-line therapy is 
TMP /SMX (trimethoprim/ sulfamethoxazole), ER/SX 
(erythromycin/ sulfisoxazole), AM/CL (amoxicillin/ 
clavulanate), cefixime, cefaclor, or CFXAX (cefuroxime 
axetil). 
What are the pathogens? 
Decisions regarding choice of antimicrobial agent 
are partly based on the most likely pathogen. The most 
probable organisms in AOM in children are: S. 
pneumonia (-35%), H. influenza (-25%), M. catarrhalis 
(-15%), Strep. Group A, S. au reus, Gram-negative rods, 
anaerobes or viruses. 1 
Why amoxicillin for fi rst-line management? 
The goal of therapy is to targe t the most likely 
organism. More than 90% of AOM in healthy children 
will resolve with amoxicillin. 2 In addition, amoxicillin 
has a reasonable cost, acceptable flavour and a 
relatively low rate of adverse effects. 
Wh y do symptoms persist? 
Prior to ini tiating second-line therapy, reasons for 
symptom persistance should be considered. Po ible 
reasons include concurrent viral infection, bacterial 
resis tance to firs t-line therapy, failure to eradicate 
sensitive bacteria, middle ear effusion, poor host 
defences or noncompliance. This last factor may be due 
to physician errors (no t explaining side effects), 
pharmacist errors (incorrect labeling) or parental 
factors (drug cost). 
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Wh y is second-line therapy used? 
There are two major reasons for initiating second-
line therapy. In some situations, incomplete treatment 
of AOM may have undesirable consequences (e.g . 
mas toidi t is or meningitis). Chi ldren wi th severe 
symptoms, who are young and febrile or 
immunocompromi ed are especially prone to this. 
Secondly, an episode of AOM might involve 
organisms tha t are resis tant to first- line th erapy. 
Children whose ymptoms persist beyond 48-72 hour , 
who have a new AOM during first-line or prophylactic 
therapy, or who have had an AOM unresponsiv to 
amoxicillin within the pas t 2 months may harbour 
resistant organisms. 3 
Strains of H. influenza, M. catarrh alis (and S. 
aureus) are resistant to fir t-line therapy because they 
produce ~lac tamase (an enzyme), w h ich h ydrolyzes 
many of the penicillins . In vitro, up to 40 % of H. 
influenzae, and 90% of M. catarrhalis produce 
~lactamase.• Up to 16% of treatment fail u res are d ue to 
~lactamase production.' Effective second-line therapy 
includes AM/CL (CL=cla ulanic acid is a ~lactama e 
inhibitor), ER/SX (erythromycin alone is ineffective), 
orTMP/SMX. 
Some strains of S. pneumonia display a n tibiotic 
resistance. In vitro, up to 40% of Pneumococci were 
resistant to TMP /SMX. 6 In addition, S. pneumonia 
may acquire resis tance to penici ll ins, secondary to 
changes in penicillin binding proteins. AM/CL would 
be an effective second-line therapy. S. pneumonia are 
infrequently resistant to erythromycin, or 
cephalosporins.7 
CEPHALOSPORINS ARE EFFECTIVE AGAINST 
MOST GRAM NEGATIVE BACILLI 
SIDE EFFECTS 
Every drug used to treat AOM has the potential to 
cause side effects (mo t commonly GI upset and rashes). 
Amoxicillin causes the fewe t side effects. However, the 
addition of Clavulinic acid increases the occurrence of 
diarrhoea . ausea, vomiting and gastritis are relatively 
common with erythromycin. Sulpha dru gs are rarely 
associated wi th Stevens-John on syndrome and bone 
marrow suppression.7 
DOSAGE 
Some of the cephalosporins and TMP /SMX have the 
advantage of twice daily dosing, compared to dosing 
three times a day common to many of the second-line 
therapies. 
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Appenclix 1. Management of acute otitis media in children'0 
Antibiotic 
First-Line Arnoxicillin 
Pivampicillin 
Second-Line TMP/ SMX 
(T rimethoprirn I SuI famethoxazole) 
ER/SX (Erythrom~/Sulfisoxazole) 
AM/ CL (Amoxic· · / Ciavulanate) 
Cefixime 
Cefaclor 
CFXAX (Cefuroxime axetil) 
Third-Line T rimethoprirn 
Clarithromycin 
Prophylaxis TMP/SMX 
Amoxicillin 
Pivampicillin 
THE CEPHALOSPORI S 
Despite being one of the better tasting preparations, 
cephalosporins are relatively expensive. In addition, 
Cefaclor is less effective than orne other antibiotics, and 
Cefixime is not very effective again t Pneumococci. 
Cefixime is very useful while travelling, because it does 
not require refrigeration.8 
MANAGEMENT PLAN 
Once the diagnosis of AOM is made, first-line therapy 
(amoxicillin or pivampicillin) is initiated for 7-10 days. If the 
patient is allergic to penicillin than a uitable econd-line 
therapy can be initia ted (ER/SX, TMP /SMX). If after 7-10 
days symptoms have subsided, then treabnent is complete. 
If symptoms fail to improve within 48-72 hours, then 
bacterial resistance is likely, and a witch to a suitable 
second-line therapy is indicated . AM/CL, or ER / SX, 
TMP / SMX could be used against f3lactamase producing 
strains. Of the e, TMP /SMX is the least expensive, 
cephalosporins are the most expensive. However, if 
penicillin resistant S. pneumonia is uspected then 
TMP / SMX may not be effective. If, at 48-72 hours, the child 
is toxic or experiencing complications then myringotomy 
and or tympanocentesis (with culture and ensitivity to 
identify the pathogen) should be considered. 
Relap e (reinfection with the same organism) within 4 
days of discontinuing therapy should be treated as failure to 
respond to therapy. However, recurrence (infection with a 
new organism) 5 to 14 days after di continuing therapy 
should be treated with first-line antibiotics. 
Persistence of effusion, or tympanic membrane 
inflammation (despite resolution of otalgia) after 10-14 day 
can be managed by continuing the same therapy for 14 to 21 
days in total. Alternatively, the patient can be observed 
without antibiotics. Persistence i often viral in origin, but 
predisposes to bacterial infection. 
1hree or more infections in 6 months or 4 infections per 
year without chronic effusions between episodes is treated 
acutely as failure to respond . Thi is followed by 
chemoprophylaxis and or tympanostomy and 
m yringotomy.• C&S resu lts are u ed to guide further 
management. 
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Dose Cost per day 
($/ kg) 
40 mg/ kJ / d, divided j h O.o3 
4060 mg kg / d, divid ql2h 0.070.11 
812 mg/ kg/ d, divided q12h 
40 mg/ kg/ d, divided q68h 0.020.03 
40 mg/ kg / d, divided q8h 0.10 
8 mg/kg/d, divided q1224h 0.15 
40 mg / kg/ d, divided q812h 0.130.23 
40 mg/kg/d , divided q12h 0.17 
not in children <12 years old 0.01 
15 mg / kg / d, divided q12h 0.09 
half the usual 
therabutic 
dose id 
CONCLUSION 
Despite increasing resistance to antimicrobial therapy, 
most children with acute otitis media should respond to 
amoxicillin within 48-72 hours. If this is not the case then 
infection with resistantS. pneumonia, H. influenza or M. 
catarrhalis should be suspected. Second-line therapy with 
TMP / SMX ER/SX or AM/ CL can be initiated depending 
on the suspected pathogen . Cephalosporins are an 
expen ive alternative. If there is persistent or recurrent 
fever or otalgia then tympanocentesis or myringotomy can 
be used to guide antimicrobial therapy. 
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P r oblem Sol vi ng 
A CASE OF 
EXPERIENCE 
THE 
" A FRIGHTENING 
IN THE MIDDLE OF 
NIGHT" 
A 2-year-old male child is brought by his mother to the Emergency Department at 0400h. The mother describes an episode during which the child 
stopped breathing, turned red, and wa gagging. She was 
afraid he might die. 
PLEASE STOP A D A SWER THE FOLLOW! G 
QUESTIO S: 
1. arne the condition. 
2. Define the condition. 
3. What is your differential diagnosi ? 
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Re idency Program Director 
Department of Radiation Oncology 
(519) 685-8650 
The Ontario Cancer Treatment and Re earch Foundation 
by Paul Collins, Meds '99 
On examination, the child has a temperature of 37.5, 
BP 95/60, and HR 75. He is slightly cyanosed. Head and 
neck examination normal. o signs of airway ob truction. 
Chest exam normal. eurological exam unremarkable. 
PLEASE STOP A D A SWER THE FOLLOW! G 
QUESTIO S: 
4. What are normal BP and HR for a 2-year-old? 
5. Explain the bradycardia. 
6. Explain the cyanosis. 
The child is admitted to ho pital, a complete workup 
is ordered and he is monitored for several nights. Pain is 
never observed by hospital taff. ASSUME that, despite 
exhausting all available diagno tic means, no pathological 
explanation for the initial pain wa found. 
PLEASE STOP AND THINK ABOUT THIS QUESTIO 
7. What do you do now? 
The mother is a 26-year-old unemployed single 
parent. Her parents put her up for adoption when he 
was 5 years old, and she has not been in contact with 
them since. She lives alone because her husband left a 
year ago and is seeking a divorce. They had one other 
child that died of SIDS. She feels depre sed and lonely. In 
the past year her son has been admitted to hospital for 
multiple problems including failure to thrive, lethargy 
and recurrent diarrhoea. Throughout the interview he 
insists that she is a "good parent" and that she "loves her 
son". She also comments that she "doesn't know what 
she'd do without the doctor's help". A psychiatric consult 
is ordered. 
PLEASE STOP A D A SWER THE FOLLOW! G 
QUESTIO S: 
8. What rare p ychiatric di order does this cenario 
suggest? 
9. De cribe the condition. 
10. How could pain, failure to thrive, lethargy, and 
diarrhoea be exogenously induced? 
11. What is the role of the physician in this situation? 
12. Discuss principles of intervention. 
The mother is currently under psychiatric care and 
the child will reside in a foster-home indefinitely until her 
recovery. 
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ANSWERS TO CASE STUDY 
1. Apparent Life-Threatening Event (ALTE). 
2. An episode characterized by apnoea (central or 
obstructive), change in colour (usually cyanosis or pallor, 
occasionally erythema or plethora), change in muscle tone 
(limpness or stiffness), and choking or gagging. The episode 
is frightening to the observer. In some cases the observer 
fears that the infant has died. Previously used terms include 
"aborted crib death" or "near-miss SIDS". 
3. Common causes of ALTE (from Most to Least 
Common) include: Gastroe ophageal Reflux (GER); 
eurologic (seizure disorder); Infectious (meningitis); 
Re piratory [respiratory syncytial virus (RSV), pertussis, 
pneumonia, congenital central hypoventilation syndrome 
(CCHS)], Airway Abnormality or Obstruction; Vasovagal 
Syndrome; Cardiac (Wolff-Parkinson-White syndrome, 
arrhythmia), Metabolic-Endocrinologic; Munchausen 
syndrome by proxy. 
4. ormal BP 90/60 & HR 110 in the 1-2 year age group. 
5. Bradycardia is defined as abnormally slow heart rate. 
The combination of repeated episodes of apnoea and 
hypoxia eventually slows the heart ra te, an effect mediated 
by the vagus nerve. 
6. Cyanosis is defined as blue, grey, or purple 
discoloration of the skin due to reduced haemoglobin in the 
blood. Caused by hypoxia and hypercapnia secondary to any 
condition interfering with air entry into the respiratory tract. 
7. Whenever comprehensive physical examination and 
investigations fail to reveal the aetiology of childhood 
P r oblem Solving 
disorders such as apnoea or an AL TE, non-medical causes 
must be considered. Obtain a detailed psychosocial history 
of the mother. 
8. Munchausen Syndrome by Proxy (MSP). 
9. MSP is a recently described rare form of child abuse 
in which a caregiver (almost always the mother) fabricates 
or induces symptoms in a child in order to attract medical 
attention. The condition is unders tood in terms of the 
mother's need for a relationship with a physician that is 
rooted in a profound sense of early abandonment. The 
infant in this sadoma ochistic interaction is dehumanized 
and is used as a fetishistic object to control the relationship. 
MSP is a serious form of child abuse that may remain 
undetected for years. Victims suffer serious physical and 
psychological damage and sometimes even death. 
10. Apnoea (smothering), failure to thrive (starvation), 
lethargy {dehydration, malnutrition), diarrhoea (laxatives). 
11. Physicians must be aware that MSP exists, can 
present in the form of anything, and should be considered 
as a diagnosis in ca es that do not make medical sense. 
MSP is a severe form of child abuse and must be reported 
to local Child Protection Service when the child is 
endangered. Physicians play a key role in identifying these 
children and recommending the best course of action to the 
rest of the system. 
12. After the condition is confirmed, a multidisciplinary 
team aims to protect the abused child and change the 
pathological parent-child relationship. Comorbid psychiatric 
conditions in the illness perpetrators and psychological 
manifestations in the children must be addressed. 
MEDICAL-.. SCHOOL-.. IS-.. JUST-.. THf-..BfGINNING 
our reaJ education s tart once you + :::::::::, raduat . You'll need to know how to 
un your practice a nd manage your life . 
hat's where MD Manageme nt , the 
Canadian Medical Associations financial 
subsid iary. can help. We have the expert ise to 
lOur ji11muia I partJZer acrtJJJ tb~ cottJZtry 
MD Management staffs branch offices across 
the country so you'll have a financia l partner 
in most major centres. Talk to one of our con-
sultant about gening a practice loan, building 
an investment portfolio and saving tax. 
help you get a head and stay there. , 
· "Is 1~'// iJo wbat~•·u it tak u 
. t"on and detat 
lOu may b~ a iJot:tor, For l1tfor111G ; Q' • 9' s' to a1wwu your quutioiW 
hw •~ Y"" a''""'~,_., 1-800· J I MD M ...... ~_,·, P~•i~ ~...--
MD M anagements business ment hotline gives you access to one of 
education program combines Canada's leading consultants. Call our toll free 
seminars a nd publications to give y ou the right line w henever y ou like, ask your question a nd 
mix of information you'll need to run a medical you 'll have a n answer within two business days. 
practice a nd mind y our business. • 
"""' + '"'""" 
U. W.O. Medical Journal 66 (1) 1996------------------------- 43 
P r ob l em So lvi ng 
LIGHTNING STRIKES FOUR TIMES 
You have a new patient, an 18-year-old woman, who has recently married and wishes to begin family planning. She has a history of Tetralogy of Fallot 
with surgery having been performed in early childhood. 
She wants to know if she is at risk of having a child with a 
congenital heart defect and what can be done to increase 
her chances of having a healthy child. 
1. What further information is necessary before you can 
answer her questions? She has been relatively healthy 
and does not drink or smoke. She is on no medications. 
Although she has had intermittent complaints of 
dyspnoea and chest pain, a recent treadmill exercise 
ECG showed excellent endurance to physical effort. She 
is followed annually by her cardiologist who feels there 
is no contraindication to pregnancy. Her family history 
is negative for any individuals with congenital heart 
defect or other congenital malformations. 
2. What is her risk of having a child with: 
(a) congenital heart defect? 
(b) neural tube defect? 
(c) Trisomy 21? 
3. What general and specific recommendations would you 
have regarding management of a pregnancy? 
A year later, she returns, two months pregnant, having 
been on folic acid supplements. Fetal echocardiogram at 
18 weeks demonstrates the presence of hypoplastic left 
heart syndrome. She and her husband are coun elled 
regarding the extremely poor prognosis for their baby and 
they elect to continue the pregnancy. Their daughter is 
born at term weighing 5 pounds and dies at 3 days of age. 
4. Has her recurrence risk for congenital heart defect 
changed in view of thi history? 
Two years later, she is again pregnant and you follow 
the previous plan of management. This time the fetal 
echocardiogram reveals an apparently normal fetal heart. 
She gives birth at term to a 6 lb. 4 oz son. At his 1 month 
checkup, you detect a heart murmur. The child is found to 
have a patent ductus arteriosus (PDA). The parents are 
rea sured that this is a minor congenital heart defect but he 
requires surgical repair. 
5. Are you becoming suspicious that there may be some 
underlying genetic disorder or is this mother just 
unlucky? 
ABOUT THE AUTHOR 
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by Dr Victoria Mok Siu , MD, FRCP, FCCMG 
Your patient becomes pregnant for the third time. A 
routine ultrasound detects only one kidney but fetal 
echocardiogram is normal. She delivers a healthy 6 lb. 2 oz 
boy. As a precaution, you refer him for a cardiology 
assessment and he is found to have a small ventricular 
septal defect. His maternal grandmother now comes to see 
you and insists there must be a reason for all of the heart 
defects in this family. You start to reassess the situation. 
ow that you think of it, there do seem to be more than 
just heart problems. 
The child with the PDA has been slow to talk and it is 
difficult to understand his speech. His mother states that she 
herself required speech therapy throughout school and her 
speech is still quite hypemasal. She describes herself as a 
"slow learner". The baby with the VSD and unilateral renal 
agenesis tend to regurgitate frequently through his nose. 
6. What type of problem is suggested by these symptoms? 
On looking do ely at the mother and two children, 
you note that they share some physical characteristics. 
They are not strikingly dysmorphic but they do have small 
ears and hypertelorism (increa ed distance between the 
pupils). Mother has a long nose and high nasal bridge. 
F/G. l 
7. What is your diagnosis? 
8. What tests will you order to confirm this diagnosis? 
9. ow that you have a definite diagnosis, what is the 
recurrence risk? 
10. Does this alter your plan of management for future 
pregnancies? 
11. Your patient's sister is now pregnant and very worried 
about her risk of having a child with congenital heart 
defect. What can you tell her? 
12. Is this just another one of those esoteric cases that 
you'll never see in practice? 
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ANSWERS TO CASE STUDY 
1. Family hi tory of congenital heart defects, other 
congenital malformation , recurrent miscarriages 
or stillbirth 
History of making/ alcohol intake 
Exercise tolerance, recent cardiac evaluation 
2. (a) In general, the risk of having a child with 
congenital heart defect if one parent is affected is 
approximately 1 in 30 (3%). 
(b) Based on her negative family history, her risk 
of having a child with neural tube defect is the 
arne a that of the general population, 
approximately 1 in 800. 
(c) Her risk of having a child with Tri omy 21 
depends on her age at delivery. At a maternal age 
of 20 year , the risk is about 1 in 1650. 
3. GE ERAL: 
(i) periconceptional folic acid upplements at a daily 
dose of 1 mg PO to decrea e the ri k for neural 
tube defect. 
(ii) maternal serum screening at 15 1 / 2 weeks to 
screen for risk of neural tube defect and Down 
yndrome. 
SPECIFIC: 
(iii) fetal echocardiogram at 18 week to screen for 
major cardiac malformation . 
(iv) careful monitoring of her cardiac status and SBE 
prophylaxis for any dental extraction and 
potentially eptic surgical procedure . 
4. Yes. With an affected mother and child, the 
recurrence risk is definitely increased to at least 
10%. 
5. Patent ductus arteriosus is quite common in 
premature infants, and usually closes 
spontaneously or with the aid of indomethacin. 
However, PDA is rare in term infant . You hould 
now be con idering very strongly the possibility 
of a pecific underlying diagnosis . 
6. Velopharyngeal insufficiency. You should look for 
evidence of any palatal problems such as a cleft 
palate (overt or submucou ) or bifid uvula . On 
e amination, mother doe have a ubmucous cleft 
palate. 
7. The combination of velopharyngeal insufficiency 
with submucous cleft palate, cardiac defect, 
learning problems, and facial features section 
(long nose with prominent nasal root, ear 
anomalie ) i typical for Shprintzen 
(velocardiofacial) yndrome, first described in 
1978. In 1992, Shprintzen syndrome was found to 
be a sociated with a deletion of part of the long 
arm of chromo orne 22. Other congenital 
malformation syndromes which may have the 
same 22q11.2 deletion include DiGeorge 
syndrome and CHARGE association. All of the e 
di orders are now grouped under the acronym of 
CATCH 22 which describes the various systems 
that may be affected, i.e. Cardiac, Abnormal 
facies, Thymic hypopla ia, Cleft palate , 
Hypocalcemia (due to hypoparathyroidism). 
Affected structures are all derivatives of the third 
and fourth pharyngeal pouches. There is 
con iderable intrafamilial variation (as 
demonstrated by this case his tory) as well as 
interfamilial variation. In the mo t evere cases, a 
newborn may present with hypocalcemic eizures, 
recurrent infection due to decreased T cell 
function, and major congenital heart defect. Much 
milder ca es may not be diagnosed until a child i 
inve tigated for learning problem and speech 
delay. 
8. Occa ionally, the deletion may be detected on 
routine chromosome karyotyping, especially if 
you indicate that you are interested in the 22q 
region. However, in the majority of cases, pecial 
reque t mu t be made for a FISH (Fluorescence In-
Situ Hybridization) tudy, again specifying the 
22q region. The cytogenetics laboratory will 
prepare a metaphase chromosome spread, 
hybridize to a 22q11.2 D A probe, and utilize a 
fluorescent marker to determine whether or not 
there i a deletion ( ee illustra tion). 
9. In this family, the mother was proven to have a 
22q11.2 deletion which occurred de novo (neither 
of her parents had the deletion). Both of her sons 
(and likely her daughter) inherited the deletion . In 
any future pregnancy, she will have a 50% ri k of 
passing on the deletion. Similarly, her affected 
children will have a 50% risk of passing on the 
deletion to their offspring. 
10. Chorionic villus sampling at 10 to 12 weeks or 
amniocentesis at 15 to 18 weeks could be offered 
to determine if the fetus has inherited the deletion 
and, if so, fetal echocardiogram would be 
indicated to determine the severity of congenital 
heart defect. 
11. Since this is a de novo dele tion in your patient, 
her unaffected sister has the arne risk as that of 
the general population for having a child with 
congeni ta l heart defect. o special prenatal 
inve tigations are indicated for the ister. 
12. o. Deletions of 22q have been found in up to 5% 
of all newborns with heart defects and may 
represent the mo t common chromo orne 
abnormality after Down syndrome (Trisomy 21) . 
The spec trum of problems seen in CATCH 22 
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results in many different specialists having the 
opportunity of assessing and diagnosing a patient: 
E T, cardiology, pia tic urgery, endocrinology, 
neurology, immunology. Undoubtedly, there are 
many undiagnosed cases, particularly as this 
deletion yndrome is just starting to be 
recognized. 
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Vocabulary 
The Vocabulary Section of this issue was compiled with the help of health care providers in the area of paediatric medicine from seven different countries. 
The forum for this exchange of ideas was an Internet chat 
channel called International Pediatric Chat. The website 
for this organization can be found at the following URL: 
http/ /:www.pedschat.com. Instructions on how to 
access the chat channel are provided at that site. Below is 
an excerpt from this innovative new service. 
"International Pediatric Chat (IPC) is an organization 
of pediatric professionals who use live Internet typing, 
voice chat, and hopefully someday video conferencing as 
a means of communicating with each other. It was started 
May 16, 1996 by Dr Julius Edlavitch from Minneapolis, 
Minnesota. It is like a giant doctors' lounge where 
pediatricians, pediatric nurse practitioners, pediatric 
specialists, pediatric nurses, and other medical 
professionals interested in children meet. Below are some 
of the benefits and features section of IPC. 
live socialization of the members on a regular 
basis to develop professional friendships never before 
possible 
professionals can drop into this lounge on a 24 
hour a day basis, 7 days a week, to share medical and 
personal information 
medical education sessions with international 
perspectives promote free thinking and help 
professionals approach some of their dilemmas with new 
and culturally diverse perspectives 
need help? 24 hours 7 days a week, pediatric 
professionals can get live help from others; one can share 
cases like never before". 
PAEDIATRIC MEDICAL VOCABULARY 
1. LANUGO 
a. fetal hair 
b. an endemic granulomatous disease 
c. a bundle of fibers in the immature CNS 
d. ubiquitous colour of neonates' eyes 
2. PRUNE-BELLY DISEASE 
a. diarrhea 
b. congenital truncal maroon discoloration 
c. Eagle Barrett Syndrome 
d. eponym for appearance of baby's skin after 
prolonged immersion in bath water 
ABOUT TilE AUTilOR 
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3. NIPPLE CONFUSION 
a. a.k.a. Triple nipple disease 
b. infant thinks his/her nostrils are nipples 
c. infant is born with extra nipples 
d. infant refuses mother's nipple after experiencing 
bottle 
4. DIASTEMATOMYELIA 
a. hernia of rectus muscle 
b. an unusual constitutional susceptibility to a 
particular disease 
c. anomaly resulting in Tethered Cord Syndrome 
d . the rest period of the cardiac cycle of a neonate, 
prior to systolic muscle contraction 
5. SYNOPHYRS 
a. converging brain cells 
b . secondary sensations accompanying actual 
perceptions 
c. congenital fusion of the testes into one mass 
d . eyebrows that meet in the midline 
6. HURLER DISEASE 
a. overuse syndrome typified by synovitis of biceps 
brachialis muscle 
b. congenital lysosomal storage disease 
c. a.k.a. congenital pyloric stenosis 
d . plague to hit Blue Jay pitchers in 1994 season 
7. MONGOLIAN SPOTS 
a. dermatitis associated with Mongolism (Trisomy 21) 
b. certain bars and restaurants found on Richmond St. 
c. transient blue/black pigmented macules 
d. neonatal red raised lesion 
8. TRICHOTILLOMANIA 
a. compulsive mischievous behaviour 
b. affective disorder triggered by Trichomonas 
c. compulsive pulling out of one's hair 
d. meaningless repetition of words and phrases 
9. TALIPES EQUINOVARUS 
a. flatfoot 
b. clubfoot 
c. fear of horses 
d . congenital lesion at level of cauda equina 
10. ELEKTRA COMPLEX 
a. Pseudo-Freudian condition of morbid daughter-
father attachment 
b. intendo-caused thumb synovitis 
c. side effect in some paediatric electroconvulsive 
therapy recipients 
d. complex of eschar and gangrenous tissue after an 
electric bum 
48 
------------------------ U. W .O. Medical Journal 66 (1) 1996 
~N~rvasc · 
tamlodtptne besylate pftzen 
Brief Prescribing Information 
NORVASC 
tamlodipine besylate) 
Tablets 2-5. 5 and 10 mg 
AntihypertensN-e-Antianginal Agent 
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taking medications known to lower blood pressure. 
Peripheral Edema 
Mild to moderate peripheral edema was the most common adverse event in the clinical trials (see ADVERSE 
REACTIONS). The incidence of peripheral edema was dose-dependent and ranged in frequency from 3.0 to 10.8% 
in 5 to 10 mg dose range. Care should be taken to differentiate this peripheral edema from the effects of increasing 
left ventricular dysfunction. 
Use in Pregnancy 
Although amlodipine was not teratogenic in the rat and rabbit some dihydropyridine compounds have been found 
to be teratogenic in animals. In rats, amlodipine has been shown to prolong both the gestation period and the 
duration of labor. There is no clinical experience with NORVASC in pregnant women. NORVASC should be used 
during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus. 
Nursing Mothers 
It is not known whether amlodipine is excreted in human milk. Since amlodipine safety in newborns has not been 
established, NORVASC should not be given to nursing mothers. 
Use in Children 
The use of NORVASC is not recommended in children since safety and efficacy have not been established in 
that population. 
Use in Elderly 
In elderty patients (~5 years) clearance of amlodipine is decreased with a resuh.ing increase in AUC. In clinical 
trials the incidence of adverse reactions in elderly patients was approximately 6% higher than that of younger 
population (<65 years). Adverse reactions include edema, muscle cramps and dizziness. NORVASC should be used 
cautiously in elderly patients. Dosage adjustment is advisable (see DOSAGE AND ADMINISTRATION!. 
Drug Interactions 
Beta-blockers: When beta-adrenergic receptor blocking drugs are administered concomit.antty with NORVASC, 
patients should be carefully monitored since blood pressure lowering effect of beta-blockers may be augmented by 
amlodipine's reduction in peripheral vascular resistance. 
Digoxin. Cimetidine, Warfarin: Ptlarmacokinetic interaction studies in healthy volunteers have indicated: 
• amlodipine did not change serum digoxin levels or digoxin renal clearance. 
• cimetidine did not after the pharmacokinetics of amlodipine. 
• amlodipine did not change warfarin induced prothrombin response time. 
ADVERSE REACTIONS 
NORVASC (amlodipine besytate) has been administered to 1.714 patients (805 hypertensive and 909 angina 
patients) in controlled clinical tria ls (vs placebo alone and with active comparative agents). Most adverse 
reactions reported during therapy were of mild to moderate severity. 
Hypertension 
~n the 805 hyp~rtensive patients treated with NORVASC in controlled clinical trials, adverse effects were reported 
10 29.9% of patients and required discontinuation of therapy due to side effects in 1.9% of patients. The most 
common adverse reactions in controlled clinical trials were: edema (8.9%), and headache {8.3%). 
The following adverse reactions were reported with an incidence of ~.5% in the controlled clinical trials 
program (n=805j: 
Cardiovascular. edema (8.9%1. palpitations (2-0%1, tachycardia (0.7%1. postural dizziness (0.5%1. Skin and 
Appendages: pruritus (0.7%). Musculoskeletal: muscle cramps (0.5%). Central and Peripheral Nervous 
System: headache (8.3%), dizziness (3.0%). paresthesia (0.5%1. Autonomic Nervous System: Hushing (3.1%1. 
increased sweating (0.9%1, dry mouth (0.7%1. Psychiatric: somnolence (1.4%1. Gastrointestinal: nausea (2.4%1. 
abdominal pain (1.1%1. dyspepsia (0.6%1. constipation (0.5%1. General: fatigue (4.1%), pain (0.5%1. 
Angina 
In the controlled clinical trials in 909 angina patients treated with NORVASC. adverse effects were reported in 
30.5% of patients and required discontinuation of therapy due to side effects in 0.6% of patients. The most 
common adverse reactions reported in controned clinical trials were: edema (9.9%} and headache (7.8%). 
The following adverse reactions occurred at an incidence of ~.5% in the controlled clinical trials program 
(n=9091: 
Cardiovascular. edema (9.9%1. palpitations (2.11%), postural dizziness (0.6%1. Skin and Appendages: rash (1 .0%1. 
pruntus (0.8%). Musculoskeletal: muscle cramps (1 .0%). Central and Peripheral Nervous System: headache 
17.8%1. dizziness (4.5%1. paresthesiall .ll'41. hypoesthesia (0.9'!11. Autonomic Nervous System: fiushing (1.9%1. 
Psychiatric: somnolence (1 .2%), insomnia {0.9%1. nervousness (0.7%1. Gastrointestinal: nausea (4.2%), 
abdominal pain (2.2%1. dyspepsia (1 .4%1. diarrhea (1 .1%1. flatulence (1 .0%1, constipation (0.9%). Respiratory 
System: dyspnea (1.1%1. Special Senses: abnormal vision (1 .3%1. tinnitus (0.6%1. General: fatigue (4.8%1. 
pain (1.0%1, asthenia (1 .0%1. 
NORVASC has been evaluated for safety in about 11 ,000 patients with hypertension and angina. 
The foii<Ming events occurred in <1% but >0.1% of patients in comparative clinical trials (double-blind 
comparative vs placebo or active agents; n = 2.615) or under conditions of open trials or marketing experience 
where a causal relationship is uncertain. 
Cardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrilation), bradycardia, hypotension, 
peripheral ischemia, syncope, tachycardia, postural diuiness, postural hypotension. Central and Peripheral 
Nervous System: hypoesthesia, tremor, vertigo. Gastrointestinal: anorexia, constipation, dysphagia, vomiting, 
gingival hyperplasia. General: asthenia ', back pain, hot flushes, malaise, rigors, weight gain. Musculoskeletal 
System: arthralgia, arthrosis, myalgia. Psychiatric: sexual dysfunction {male' and female), insomnia, nervous-
ness, depression, abnormal dreams, anxiety, depersonalization. Respiratory System: epistaxis. Skin and 
Appendages: pruritus', rash erythematous, rash maculopapular. Special Senses: conjunctivitis, diplopia, eye 
pain, tinnitus. Urinary System: micturition frequency, micturition disorder, nocturia. Autonomic Nervous System: 
dry mouth, sweating increased. Metabolic and Nutritional: thirst Hemopoietic: purpura. 
tThese events occurred in less than 1% in placebo controlled trials, but the incidence of these side effects was 
between 1% and 2% in all multiple dose studies. 
The following events occurred in g).1% of patients: cardiac failure, skin discoloration, urticaria, skin dryness, 
alopecia, twitching, ataxia, hypertonia, migraine, apathy, amnesia, gastritis, increased appetite, coughing, 
rhinitis, parosmia, taste perversion, and xerophthalmia. 
SYMPTOMS AND TREATMENT OF OVERDOSAGE 
Symptoms 
Overdosage can cause excessive peripheral vasodilation with marked and probably prolonged hypotension and 
possibly a reflex tachycardia. In humans, experience with overdosage of NORVASC (amlodipine besylate) is limited. 
When amlodipine was ingested at doses of 105-250 mg some patients remained normotensive with or without 
gastric lavage while another patient experienced hypotension (90150 mmHg) which normalized following plasma 
expansion. A patient who took 70 mg of amlodipine with benzodiazepine developed shock which was refractory 
to treatment and died. In a 19 month old child who ingested 30 mg of amlodipine (about 2 mglkg) there was no 
evidence of hyl)<ltension but tachycardia (180 bpm) was observed. Ipecac was administered 3.5 hrs after ingestion 
and on subsequent observation tovemight) no sequelae were noted. 
Treatment 
Clinically significant hypotension due to overdosage requires active cardiovascular support including frequent 
monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume 
and urine output A vasoconstrictor (such as norepinephrine) may be helpful in restoring vascular tone and 
blood pressure, provided that there is no contraindication to its use. As NORVASC is highly protein bound, 
hemodialysis is not likely to be of benefrt Intravenous calcium gluconate may be beneficial in reversing the 
effects of calcium channel blockade. Clearance of amlodipine is prolonged in elderly patients and in patients 
with impaired lfver function. Since amlodipine absorption is stow, gastric lavage may be worthwhile in some cases. 
DOSAGE AND ADMINISTRATION 
Dosage should be individualized depending on patient's tolerance and responsiveness. For both hypertension 
and angina, the recommended initial dose of NORVASC (amlodipine besyfate) is 5 mg once daily. If necessary, 
dose can be increased after 1-2 weeks to a maximum dose of 10 mg once daily. 
Use in the Elderly or in Patients with Impaired Renal Function 
The recommended initial dose in patients over 65 years of age or patients with impaired renal function is 5 mg 
once daily. If required, increasing in the dose should be done gradually and with caution {see PRECAUTIONS). 
Use in Patients with Impaired Hepatic Function 
Oosage requirements have not been established in patients with impaired hepatic function. When NORVASC is 
used in these patients, the dosage should be carefully and gradually adjusted depending on patient's tolerance 
and response. A lower starting dose of 2.5 mg once daily should be considered (see WARNINGS). 
DOSAGE FORMS 
Ava i labil ity 
NORVASC is available as white octagonal tablets containing amlodipine besylate equivalent to 2.5, 5 and 10 mg 
amlodipine per tablet The respective tablet strengths are de bossed on one tablet face as .. NRV 2.5 .. , .. NRV 5· 
and "NRV 10" with "Pfizer· on the opposite face. The 5 mg tablet is scored. Supplied in white plastic (high density 
polyethylene) bottles of 100 tablets for each strength. Also the 5 mg and 10 mg are supplied in bottles of 250 tablets. 
STORAGE 
Store at 15-JO"C. Protect from light 
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Problem Solving 
ANSWERS TO PAEDIATRIC 
VOCABULARY 
1. 
2. 
3. 
4. 
a) The fine hair on the body of a fetus. 
c) Also known by the eponym Eagle Barrett 
Syndrome; congenital anomaly whicn gives the 
abdomen a wririkled appearance re embling dried 
fruit; consists of bilateral megaureter, 
hY.dronephrosis, and may include megabladder, 
bilateral cryptorchidism, and/ or mega urethra. 
d) Because of different mechanics invol ed in 
sucking from a bottle, an infant switched to breast 
feeding may refuse to latch onto the mother's nipple. 
c) A malformation in which the spinal cord is split by 
bone spicules or a fibrous band. This condition and a 
lipomatous tumor produce Tethered cord syndrome, 
with resultant abnormalities of distal sensation, gait, 
and bladder or bowel function. 
5. d) A term used to describe the specific 
dysmorphology of the face in which the eyebrows 
meet in the miilline. 
6. 
7. 
8. 
9. 
b) Deficiency of the enzyme alpha-L-Iduronidase is 
associated with kyphosis and profound loss of CNS 
function. Onset is at about 1 year; the cornea appears 
cloudy, and hepatosplenomegaly is present. 
c) Mongolian spots are transient dark blue to black 
pigmented macules seen over the lower back and 
buttock in as many as 90% of black, Indian, and 
oriental infants. 
c) This is a condition in which one is compelled to 
pull out one's hair as a means of relieving the anxiety 
caused by persistent intrusive thoughts. 
b) Clubfoot may be congenital, teratologic, or 
po itional. Examination of the infant clubfoot 
demonstrates hindfoot equinus and varus, forefoot 
adduction, and variable rigidity. 
10. a) This a Freudian condition which is roughly parallel 
to the gender-reversed Oedipal complex; a female 
child's morbid attachment to the parent of the 
opposite sex, and her jealousy towards the parent of 
the same sex. 
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At Picker, our Outlook is diHerent. 
~UTLOOK 
The Outlook system is a new concept in whole 
body MR imaging. The economical, C-style 
0.23 Tesla, cryogen free electromagnet has a 
bigger gap and wider sight lines for greater 
patient comfort. The system also features the 
latest pha ed array imaging capabilities. 
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'Roche'. fedicallnformation Departrnem 
announces a new service: 
Fax On Demand. 
You now have a to information on the mo t 
commonlv as ·ed qu tions onceming 'Roche' products. 
Your 'Roche' representative can prm.;de you ~;th a guide to the 
sen;ce or a list of to pi can be obtained from 
the 'Roche' Fax On Demand tern. Dial 
ROCHEFX (I 762-4339) 
and get the facts fast! 
Another example of the 'Roche· commitment to service. 
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